Heteroarylaminopyridinol derivatives and pharmaceutical compositions containing the same as active ingredients for preventing or treating autoimmune diseases

By preparing heteroarylaminopyridinol derivatives, the problem of the lack of effective and low-cost oral therapeutic agents in the prior art has been solved, and effective treatment of inflammatory bowel disease and rheumatoid arthritis has been achieved, especially by inhibiting the adhesion of TNF-α and IL-6.

CN114450275BActive Publication Date: 2024-11-19INNOVO THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080067429.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-09-24
Filing Date
2020-09-24
Publication Date
2024-11-19
Estimated Expiration
2040-09-24

AI Technical Summary

Technical Problem

There is a lack of effective and low-cost oral therapeutic agents for the treatment of inflammatory bowel disease and rheumatoid arthritis in the current technology, especially targeted drugs for TNF-α and IL-6, which have problems of inconvenient administration and high cost.

Method used

Heteroarylaminopyridinol derivatives have been developed, and through preparation methods including reacting specific compounds, they form activities that inhibit TNF-α or IL-6-induced monocyte adhesion to intestinal epithelial cells, for use in the preparation of pharmaceutical compositions or health functional foods to prevent or treat autoimmune diseases.

Benefits of technology

Heteroaryl aminopyridinol derivatives have shown therapeutic effects on inflammatory bowel disease and rheumatoid arthritis, and can inhibit the adhesion of TNF-α or IL-6, providing a safe, effective and low-cost treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114450275B_ABST
    Figure CN114450275B_ABST
Patent Text Reader

Abstract

The present invention relates to a heteroarylaminopyridinol derivative and a pharmaceutical composition containing the heteroarylaminopyridinol derivative as an effective ingredient for preventing or treating autoimmune diseases, particularly inflammatory bowel disease, rheumatoid arthritis, etc. The heteroarylaminopyridinol derivative has an excellent effect of inhibiting TNF-α or IL-6-induced monocyte adhesion to intestinal epithelial cells, and has been shown to have a therapeutic effect on inflammatory bowel disease and rheumatoid arthritis in vivo. Therefore, the heteroarylaminopyridinol derivative can be advantageously used to treat autoimmune diseases, particularly inflammatory bowel disease or rheumatoid arthritis.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art Technical Field

[0002] The present invention relates to heteroarylaminopyridinol derivatives and pharmaceutical compositions comprising the same as active ingredients for preventing or treating autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis.

[0003] Description of Related Technology

[0004] Immunity is one of the self-protection systems of living bodies against all foreign polymers that invade or are injected into living tissues. All normal individuals do not produce harmful reactions to antigens that constitute themselves, but they have the ability to recognize non-self antigens, react to them, and remove them. However, if the host's immune system cannot distinguish between foreign antigens and self antigens and induces an abnormal immune response, the immune cells in the body attack their own cell components and cause various diseases, which are called autoimmune diseases.

[0005] Autoimmune diseases are caused by a variety of reasons, such as heredity, stress, hormones, heavy metals, food, infection and pesticides, accounting for about 5 to 8% of the world's population. Examples of autoimmune diseases include inflammatory bowel disease, autism, asthma, type 1 diabetes, rheumatoid arthritis, polymyalgia rheumatica, ankylosing spondylitis, psoriatic arthritis, psoriasis, eczema, scleroderma, vitiligo, multiple sclerosis, IL-17-induced dementia, peripheral neuritis, uveitis, dry eye syndrome, organ transplant rejection and cancer. At present, anti-inflammatory and immunosuppressive drugs are used as therapeutic agents for autoimmune diseases, but some patients are resistant to these drugs, making treatment difficult.

[0006] Among autoimmune diseases, inflammatory bowel disease is a chronic and recurrent inflammatory disease of the digestive tract, which is divided into two diseases: ulcerative colitis and Crohn's disease. The exact cause of the disease is still unclear, but it is caused by an inappropriate immune response to bacteria in the intestines by people with genetic susceptibility. Continuous or inappropriate activation of the intestinal immune system, such as neutrophils and macrophages (which are innate immune cells) and lymphocytes (which are acquired immune cells), will eventually lead to mucosal destruction and ulcers. Under inflammatory conditions, various inflammatory cytokines are produced and secreted in the intestinal mucosa, among which TNF-α (tumor necrosis factor-α) is highly expressed in the intestinal lumen and epithelial cells of patients with ulcerative colitis. According to recent studies, TNF-α is known to play an important role in the pathogenesis of ulcerative colitis.

[0007] Infliximab, an anti-TNF-α antibody, is known to be effective not only in treating furunculosis but also in treating previously untreated Crohn's disease. However, this treatment is expensive and can cause side effects, such as fluid reactions or infectious complications, in some patients. is a Janus kinase (JAK) inhibitor that has been shown to have therapeutic efficacy in ulcerative colitis, but has been shown to be ineffective in Crohn's disease. In other words, there is still no reliable oral therapeutic agent for inflammatory bowel disease, and thus there is a need to develop an effective and low-cost oral treatment for this disease.

[0008] Among autoimmune diseases, rheumatoid arthritis is a common disease affecting approximately 1% of the adult population, and is a disease that causes joint destruction and joint deformity, ultimately leading to disability in most patients. In the pathophysiology of rheumatoid arthritis, it is reported that the occurrence of this disease is due to the activation of autoreactive T cells specific for new peptides produced by joint antigens (such as collagen or proteoglycans) after an inflammatory response based on a viral or bacterial infection. The correlation between rheumatoid arthritis and T lymphocytes, as well as B lymphocytes and synovial cells, is well known. Important cytokines associated with rheumatoid arthritis are TNF-α, IL-1, and IL-6. They increase the expression of adhesion molecules in endothelial cells to increase the influx of leukocytes into the joints, and promote the secretion of matrix metalloproteinases in synovial cells and chondrocytes to induce tissue destruction. Among the recently developed drugs for the treatment of rheumatoid arthritis, anti-TNF-α antibody preparations are the most representative, and among them, etanercept Infliximab Adalimumab It is the most commonly used drug.

[0009] However, these drugs are expensive, and the inconvenience of administration is a treatment barrier. Tofacitinib is a recently developed oral drug for the treatment of rheumatoid arthritis. In a series of clinical trials for patients with rheumatoid arthritis, diverticulitis was reported as a "serious" infection. In particular, due to reports of diverticular perforation (a situation of gastrointestinal perforation) in clinical trials, the FDA updated the "Precautions" and "Adverse Reactions" sections in December 2015. To date, no safe and effective oral therapeutic agent has been developed as a drug targeting TNF-α or TNF receptors, which have become the most effective therapeutic targets for rheumatoid arthritis. Therefore, it is required to develop an effective, low-cost, safe and efficient oral rheumatoid arthritis therapeutic agent targeting this target.

[0010] T cells play a central role in the immune system, which is a biological defense system against a variety of pathogens. T cells exist as various types of differentiated cells. Th1 cells participate in cell-mediated immunity, Th2 cells participate in humoral immunity, Th17 cells participate in infectious and inflammatory diseases, and Treg cells maintain homeostasis in the body by suppressing immunity. However, it is known that autoimmune diseases occur when the activity of Th1 cells and Th17 cells is abnormally elevated, and immune diseases occur when the activity of Th2 cells is abnormally elevated due to hypersensitivity. Since Treg cells that can regulate the activity of these cells have the characteristics of controlling inflammatory responses by inhibiting the function of abnormally activated immune cells, many experimental reports treat immune diseases by increasing the activity of Treg cells. In the case of autoimmune diseases that are not controlled by Treg cells, it has been emphasized that autoimmune disease therapeutic agents that target the inhibition of Th1 and Th17 cell activation have been developed. In addition to treating immune diseases by inhibiting the activation of T cells, therapies that control the number of cytokines secreted by immune cells, as well as therapies using antibodies targeting cytokines secreted by immune cells, are currently being developed. However, among them, the problem with the method of using antibodies is that the manufacturing cost is high and the administration is inconvenient. Therefore, there is a need to develop a novel low molecular weight compound immune disease therapeutic agent that can be orally administered and has excellent therapeutic and preventive effects on various autoimmune diseases. Summary of the invention

[0011] One object of the present invention is to provide heteroarylaminopyridinol derivatives.

[0012] Another object of the present invention is to provide a method for preparing heteroarylaminopyridinol derivatives.

[0013] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating autoimmune diseases, which comprises a heteroarylaminopyridinol derivative as an active ingredient.

[0014] In order to achieve the above object, in one aspect of the present invention, the present invention provides a compound represented by Formula 1, its isomer, its solvate, its hydrate or its pharmaceutically acceptable salt:

[0015] [General formula 1]

[0016]

[0017] (In Formula 1,

[0018] A.R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7, R 8 , R 9 and R 10 as defined in this specification).

[0019] In another aspect of the present invention, the present invention provides a method for preparing a compound of Formula 1, the method comprising the step of preparing a compound of Formula 1 by reacting a compound of Formula 2 with a compound of Formula 3, as shown in the following Reaction Formula 1:

[0020] [Reaction formula 1]

[0021]

[0022] (In reaction formula 1,

[0023] A.R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 as defined in this specification).

[0024] In another aspect of the present invention, the present invention provides a method for preparing a compound represented by Formula 1, the method comprising the following steps, as shown in the following Reaction Formula 2:

[0025] preparing a compound of Formula 4 by reacting a compound of Formula 2a with a compound of Formula 3 (Step 1);

[0026] The compound represented by Formula 1a is prepared by deprotecting the compound represented by Formula 4 obtained in the above Step 1 (Step 2); and

[0027] The compound represented by Formula 1b is prepared by reacting the compound represented by Formula 1a obtained in the above Step 2 with the compound represented by Formula 5 (Step 3):

[0028] [Reaction 2]

[0029]

[0030] (In reaction formula 2,

[0031] A.R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R9 and R 10 As defined in this specification, but R 6 Except when it is hydrogen;

[0032] The compound represented by Formula 1a is a derivative of Formula 1, wherein R 6 It is hydrogen;

[0033] The compound represented by Formula 1b is a derivative of Formula 1, but R 6 Except when it is hydrogen;

[0034] PG 1 is an alcohol protecting group selected from acetyl (Ac), benzoyl (Bz), benzyl (Bn), methylthiomethyl ether, MEM (β-methoxyethoxymethyl ether), DMT (dimethoxytrityl, [bis-(4-methoxyphenyl)benzyl]), MOM (methoxymethyl ether), MMT (methoxytrityl [(4-methoxyphenyl)diphenylmethyl]), PMP (p-methoxybenzyl ether), PIV (tert-valeryl), THP (tetrahydropyran), THF (tetrahydrofuran) and trityl (trityl, Tr); and

[0035] X is halogen).

[0036] In another aspect of the present invention, the present invention provides a pharmaceutical composition comprising a compound represented by Formula 1, an isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating an autoimmune disease.

[0037] In another aspect of the present invention, the present invention provides a health functional food, which comprises the compound represented by Formula 1, its isomer, its solvate, its hydrate or its pharmaceutically acceptable salt as an active ingredient for preventing or improving autoimmune diseases.

[0038] In another aspect of the present invention, the present invention provides a method for preventing or treating an autoimmune disease, the method comprising the step of administering a pharmaceutical composition or a health functional food to a subject in need thereof, wherein the pharmaceutical composition or the health functional food comprises a compound represented by Formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.

[0039] In another aspect of the present invention, the present invention provides the use of the above-mentioned pharmaceutical composition or health functional food for preventing or treating autoimmune diseases, wherein the pharmaceutical composition or health functional food comprises the compound represented by Formula 1, its isomer, its solvate, its hydrate or its pharmaceutically acceptable salt as an active ingredient.

[0040] Beneficial Effects

[0041] The heteroarylaminopyridinol derivatives of the present invention have excellent inhibitory effects on TNF-α or IL-6-induced monocytes adhering to intestinal epithelial cells, and have been shown to have therapeutic effects on inflammatory bowel disease and rheumatoid arthritis in vivo. Therefore, the heteroarylaminopyridinol derivatives can be advantageously used to treat autoimmune diseases, particularly inflammatory bowel disease or rheumatoid arthritis. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] FIG1 shows a set of graphs measuring the effect of the compound according to the present invention on the recovery of intestinal mucosal damage in the TNBS-induced inflammatory bowel disease animal model of Experimental Example 3, Figure 1A : A graph showing the extent of colon mucosal damage and recovery by scoring, Figure 1B : Images of colon tissue stained with hematoxylin and eosin.

[0043] Figure 2A A schematic diagram showing the administration time for measuring the pharmacological effects of the compounds of the present invention in the DSS-induced chronic enteritis animal model of Experimental Example 4.

[0044] Figure 2B A graph showing changes in body weight in the DSS-induced chronic intestinal inflammation animal model of Experimental Example 4 treated with the compound of the present invention.

[0045] Figure 2C A schematic diagram showing the morphological changes of the colon treated with the compound of the present invention in the DSS-induced chronic enteritis animal model of Experimental Example 4.

[0046] Figure 2D A graph showing the changes in intestinal weight in the DSS-induced chronic intestinal inflammation animal model of Experimental Example 4 treated with the compound of the present invention.

[0047] Figure 3A A schematic diagram showing administration time of the pharmacological effects of the compounds of the present invention in the DSS-induced acute enteritis animal model of Experimental Example 4.

[0048] Figure 3B A graph showing the changes in body weight in the DSS-induced acute intestinal inflammation animal model of Experimental Example 4 after treatment with the compound of the present invention.

[0049] Figure 3C A schematic diagram showing the morphological changes of the colon treated with the compound of the present invention in the DSS-induced acute enteritis animal model of Experimental Example 4.

[0050] Figure 3D A graph showing the changes in intestinal weight in the DSS-induced acute intestinal inflammation animal model of Experimental Example 4 after treatment with the compound of the present invention.

[0051] FIG4 shows a set of graphs showing the degree of intestinal mucosal damage obtained by hematoxylin-eosin staining of intestinal tissue after observing the shape of mouse colon in the concentration-dependent efficacy measurement experiment of Experimental Example 4, Figure 4A : Shows the colon mucosal injury degree scoring and comparison diagram, Figure 4B : Images of colon tissue stained with hematoxylin and eosin after morphological observation.

[0052] Figure 5A A graph showing the arthritis score in the rheumatoid animal model of Experimental Example 5 treated with the compound of the present invention.

[0053] Figure 5B The graph shows changes in paw thickness of mice treated with the compound of the present invention in the rheumatoid animal model of Experimental Example 5.

[0054] Figure 5C The graph shows the changes in body weight of mice treated with the compound of the present invention in the rheumatoid animal model of Experimental Example 5.

[0055] Figure 6 A set of graphs showing the weekly changes in the degree of arthritis in the rheumatoid animal model of Experimental Example 5 treated with the compound of the present invention.

[0056] 7 shows a set of images showing the degree of recovery (score) of joint tissues treated with the compound of the present invention by hematoxylin-eosin staining and safranin O staining in the rheumatoid animal model of Experimental Example 5. FIG. Fig. 7A : Images of hematoxylin-eosin staining and safranin O staining, Figure 7B : A diagram showing the degree of joint tissue recovery converted into a score.

[0057] Fig. 8A The graph shows the results of analyzing the total number of immune cells in the spleen treated with the compound of the present invention in the rheumatoid animal model of Experimental Example 5.

[0058] Figure 8B The graph shows the results of analyzing the number of inflammatory cells in the spleen treated with the compound of the present invention in the rheumatoid animal model of Experimental Example 5.

[0059] Figure 8C The graph shows the results of analyzing the number of inflammatory cells in the draining lymph nodes treated with the compound of the present invention in the rheumatoid animal model of Experimental Example 5. DETAILED DESCRIPTION

[0060] Hereinafter, the present invention will be described in detail.

[0061] Embodiments of the present invention can be modified in various other forms, and the scope of the present invention is not limited to the embodiments described below. It should be understood by those skilled in the art that embodiments of the present invention are provided to more accurately explain the present invention. In addition, unless otherwise specifically stated, "comprising" a certain element in the present invention does not exclude other elements, but may include other elements.

[0062] In one aspect of the present invention, the present invention provides a compound represented by Formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.

[0063] [Formula 1]

[0064]

[0065] (In Formula 1,

[0066] A is NR a , O or S, where R a is hydrogen or a straight or branched chain C 1-5 alkyl;

[0067] R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, halogen, straight or branched chain C 1-5 Alkyl or linear or branched C 1-5 Alkoxy, wherein the alkyl and alkoxy groups can be independently substituted with one or more halogens;

[0068] R 6 is hydrogen, straight chain or branched chain C 1-5 Alkyl, -(CH 2 )mC(=O)NH(CH 2 )nR b or -C(=O)R c , wherein the alkyl group can be substituted by one or more halogens, and m and n are independently integers from 0 to 5,

[0069] R b is hydrogen, straight chain or branched chain C 1-10 Alkyl, C 3-10 Cycloalkyl or C 6-10 Aryl,

[0070] R c It is adamantyl A 3-10 membered heterocycloalkyl containing one or more heteroatoms selected from N, O and S, C 6-10aryl, or a 5-10 membered heteroaryl containing one or more heteroatoms selected from N, O and S, wherein the aryl and heteroaryl can be independently replaced by at least one selected from halogen, straight or branched chain C 1-5 Alkyl and straight or branched C 1-5 Alkoxy group substitution;

[0071] R 7 , R 8 and R 9 are independently linear or branched C 1-5 Alkyl; and

[0072] R 10 is hydrogen or a straight or branched chain C 1-5 alkyl).

[0073] In the above formula 1, A is NR a , O or S, where R a is hydrogen or a straight or branched chain C 1-3 alkyl;

[0074] R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, halogen, straight or branched chain C 1-3 Alkyl, or straight chain or branched C 1-3 Alkoxy, wherein the alkyl and alkoxy groups can be independently substituted with one or more halogens;

[0075] R 6 is hydrogen, straight chain or branched chain C 1-3 Alkyl, -(CH 2 )mC(=O)NH(CH 2 )nR b or -C(=O)R c , wherein the alkyl group can be substituted by one or more halogens, and m and n are independently integers from 0 to 3,

[0076] R b is hydrogen, straight chain or branched chain C 1-6 Alkyl, C 3-8 Cycloalkyl or phenyl,

[0077] R c It is adamantyl A 3-8 membered heterocycloalkyl containing one or more heteroatoms selected from N, O and S, a phenyl group, or a 5-6 membered heteroaryl containing one or more heteroatoms selected from N, O and S, wherein the phenyl group and the heteroaryl group can be independently replaced by at least one selected from halogen, straight chain or branched C 1-3 Alkyl and straight or branched C 1-3Alkoxy group substitution;

[0078] R 7 , R 8 and R 9 are independently linear or branched C 1-3 Alkyl; and

[0079] R 10 is hydrogen or a straight or branched chain C 1-3 alkyl.

[0080] In the above formula 1, A is NR a , O or S, where R a is hydrogen or methyl;

[0081] R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, -Cl, -Br, -F, methyl, methoxy, -CF 3 or -OCF 3 ;

[0082] R 6 is hydrogen, methyl, -(CH 2 )mC(=O)NH(CH 2 )nR b or -C(=O)R c , where m is 1 and n is 0 or 1,

[0083] R b is hydrogen, straight chain or branched chain C 1-3 Alkyl, C 3-6 Cycloalkyl or phenyl,

[0084] R c It is adamantyl A 6-membered heterocycloalkyl group containing one or more heteroatoms selected from N, O and S, a phenyl group, or a 6-membered heteroaryl group containing one or more heteroatoms selected from N, O and S, wherein the phenyl group and the heteroaryl group can be independently replaced by at least one selected from halogen and a straight or branched C 1-3 Alkoxy group substitution;

[0085] R 7 , R 8 and R 9 is methyl; and

[0086] R 10 It is hydrogen or methyl.

[0087] In the above formula 1, R 6 is hydrogen, methyl, -(CH 2 )C(=O)NHRb or -C(=O)R c ,

[0088] R b is hydrogen, isopropyl, cyclopropyl, cyclohexyl, phenyl or benzyl,

[0089] R c It is adamantyl Morpholinyl, phenyl or pyridinyl, wherein the phenyl and pyridinyl can be independently substituted by at least one group selected from F, Cl and methoxy.

[0090] Examples of the compound represented by Formula 1 according to the present invention include the following compounds:

[0091] <1> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <2> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-1-methyl-1H-indole-2-carboxamide; <3> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-7-bromo-1H-indole-2-carboxamide; <4> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-6-chloro-1H-indole-2-carboxamide; <5> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-6-bromo-1H-indole-2-carboxamide; <6> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-fluoro-1H-indole-2-carboxamide; <7> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-bromo-1H-indole-2-carboxamide; <8> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-chloro-1H-indole-2-carboxamide; <9> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-methyl-1H-indole-2-carboxamide; <10> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethyl)-1H-indole-2-carboxamide; <11> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethoxy)-1H-indole-2-carboxamide; <12> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-6-methoxy-1H-indole-2-carboxamide; <13> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-methoxy-1H-indole-2-carboxamide; <14> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5,6-dimethoxy-1H-indole-2-carboxamide; <15> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide; <16> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-chlorobenzofuran-2-carboxamide; <17> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-bromobenzofuran-2-carboxamide; <18> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-7-methoxybenzofuran-2-carboxamide; <19> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-methylbenzofuran-2-carboxamide; <20> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide;<21> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-chlorobenzo[b]thiophene-2-carboxamide; <22> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-bromobenzo[b]thiophene-2-carboxamide; <23> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-chloro-6-methylbenzo[b]thiophene-2-carboxamide; <24> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-chloro-6-fluorobenzo[b]thiophene-2-carboxamide; <25> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3,6-dichlorobenzo[b]thiophene-2-carboxamide; <26> N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-chloro-6-methoxybenzo[b]thiophene-2-carboxamide; <27> N-(5-Hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <28> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1-methyl-1H-indole-2-carboxamide; <29> 7-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <30> 6-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <31> 6-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <32> 5-Fluoro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <33> 5-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <34> 5-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <35> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-methyl-1H-indole-2-carboxamide; <36> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethyl)-1H-indole-2-carboxamide; <37> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethoxy)-1H-indole-2-carboxamide; <38> N-(5-Hydroxy-3,4,6-trimethylpyridin-2-yl)-6-methoxy-1H-indole-2-carboxamide; <39> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-methoxy-1H-indole-2-carboxamide; <40> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5,6-dimethoxy-1H-indole-2-carboxamide; <41> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide;<42> 5-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide; <43> 5-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide; <44> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-7-methoxybenzofuran-2-carboxamide; <45> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-3-methylbenzofuran-2-carboxamide; <46> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <47> 3-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <48> 3-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <49> 3-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-6-methylbenzo[b]thiophene-2-carboxamide; <50> 3-Chloro-6-fluoro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <51> 3,6-Dichloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <52> 3-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-6-methoxybenzo[b]thiophene-2-carboxamide; <53> 3-Chloro-6-fluoro-N-(5-methoxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <54> 3-Chloro-6-fluoro-N-(5-methoxy-3,4,6-trimethylpyridin-2-yl)-N-methylbenzo[b]thiophene-2-carboxamide; <55> 3-Chloro-6-fluoro-N-(5-(2-(isopropylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <56> 3-Chloro-N-(5-(2-(cyclopropylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)-6-fluorobenzo[b]thiophene-2-carboxamide; <57> 3-Chloro-N-(5-(2-(cyclohexylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)-6-fluorobenzo[b]thiophene-2-carboxamide; <58> N-(5-(2-(Benzylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)-3-chloro-6-fluorobenzo[b]thiophene-2-carboxamide; <59> 3-Chloro-6-fluoro-N-(3,4,6-trimethyl-5-(2-oxo-2-(phenylamino)ethoxy)pyridin-2-yl)benzo[b]thiophene-2-carboxamide; <60> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl benzoate;<61> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 4-fluorobenzoate; <62> 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 3-methoxybenzoate; <63> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 4-methoxybenzoic acid; <64> 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 5-fluoropicolinate; <65> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 6-fluoronicotinate; <66> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 5-chloropicolinate; <67> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl-6-chloropicolinate; <68> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl(3R,5R,7R)-adamantane-1-carboxylate; <69> 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-ylmorpholine-4-carboxylate. ;

[0092] The compound shown in Formula 1 of the present invention can be used as a pharmaceutically acceptable salt, wherein the salt is preferably an acid addition salt formed by a pharmaceutically acceptable free acid. The acid addition salt described herein can be obtained from an inorganic acid, a non-toxic organic acid or an organic acid, the inorganic acid being for example hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid and phosphorous acid; the non-toxic organic acid being for example aliphatic mono / dicarboxylic acid, phenyl-substituted alkanoic acid, hydroxyalkanoic acid, aromatic acid and aliphatic / aromatic sulfonic acid; the organic acid being for example acetic acid, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid and fumaric acid. Examples of pharmaceutically nontoxic salts are sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, hydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, fluorides, acetates, propionates, decanoates, octanoates, acrylates, formates, isobutyrates, decanoates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, cabacates, fumarates, maleates, diate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate.

[0093] The acid addition salt according to the present invention can be prepared by conventional methods known to those skilled in the art. For example, the derivative shown in Formula 1 is dissolved in an organic solvent such as methanol, ethanol, acetone, dichloromethane and acetonitrile, and an organic acid or an inorganic acid is added thereto to induce precipitation. Then, the precipitate is filtered and dried to obtain a salt. Alternatively, the solvent and excess acid are distilled under reduced pressure and dried to obtain a salt. Alternatively, the precipitate is crystallized in an organic solvent to obtain a salt.

[0094] Pharmaceutically acceptable metal salts can be prepared using a base. Alkali metal or alkaline earth metal salts are obtained by the following method: dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution; filtering the insoluble composite salt; evaporating the remaining solution and drying. In this case, the metal salt is preferably prepared in the form of a pharmaceutically suitable sodium salt, potassium salt or calcium salt. The corresponding salt is prepared by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (e.g., silver nitrate).

[0095] In addition, the present invention includes not only the compound represented by Formula 1, but also pharmaceutically acceptable salts thereof, and solvates, optical isomers or hydrates that may be generated therefrom.

[0096] The term "hydrate" refers to a compound of the present invention or a salt thereof containing a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. The hydrate of the compound of Formula 1 of the present invention may contain a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. The hydrate may contain 1 equivalent or more of water, preferably 1-5 equivalents of water. The hydrate may be prepared by crystallizing the compound of Formula 1, its isomer, or a pharmaceutically acceptable salt thereof from water or an aqueous solvent.

[0097] The term "solvate" refers to a compound of the present invention or a salt thereof that contains a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents include those that are volatile, non-toxic, and / or suitable for human use.

[0098] The term "isomer" refers to a compound of the present invention or a salt thereof having the same chemical formula or molecular formula but different in structure or space. These isomers include structural isomers such as tautomers, R or S isomers with asymmetric carbon centers, stereoisomers such as geometric isomers (trans, cis) and optical isomers (enantiomers). All of these isomers and mixtures thereof are also included within the scope of the present invention.

[0099] The compound represented by Formula 1 of the present invention can be prepared according to the preparation method shown in the following Reaction Formula 1 or Reaction Formula 2, but this is only an example and is not limited thereto, and each preparation step can be performed using a method known to those skilled in the art.

[0100] The compound represented by Formula 1 of the present invention can be prepared by a method for preparing a compound represented by Formula 1, which comprises the step of reacting a compound represented by Formula 2 with a compound represented by Formula 3 to prepare a compound represented by Formula 1, as shown in the following Reaction Formula 1:

[0101] [Reaction formula 1]

[0102]

[0103] (In reaction formula 1,

[0104] A.R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 As defined in Formula 1).

[0105] As shown in Reaction Formula 1, the amine of the compound shown in Formula 2 reacts with Cl of the compound shown in Formula 3 to prepare the compound shown in Formula 1, wherein an amide bond is formed. The above steps can be performed using methods known to those skilled in the art, and the compound can be prepared according to the embodiments of the present invention, but this is only an example and is not limited thereto.

[0106] The compound represented by Formula 1 of the present invention can be prepared by a method for preparing a compound represented by Formula 1, which comprises the following steps, as shown in the following Reaction Formula 2:

[0107] preparing a compound of Formula 4 by reacting a compound of Formula 2a with a compound of Formula 3 (Step 1);

[0108] preparing a compound represented by Formula 1a by deprotecting the compound represented by Formula 4 obtained in the above Step 1 (Step 2); and

[0109] The compound represented by Formula 1b is prepared by reacting the compound represented by Formula 1a obtained in the above Step 2 with the compound represented by Formula 5 (Step 3):

[0110] [Reaction 2]

[0111]

[0112] (In reaction formula 2,

[0113] A.R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 As defined in Equation 1, but R 6 Except when it is hydrogen;

[0114] The compound represented by Formula 1a is a derivative of Formula 1, wherein R 6 It is hydrogen;

[0115] The compound shown in Formula 1b is a derivative of Formula 1, but R 6 Except when it is hydrogen;

[0116] PG 1is an alcohol protecting group selected from acetyl (Ac), benzoyl (Bz), benzyl (Bn), methylthiomethyl ether, MEM (β-methoxyethoxymethyl ether), DMT (dimethoxytrityl, [bis-(4-methoxyphenyl)benzyl]), MOM (methoxymethyl ether), MMT (methoxytrityl [(4-methoxyphenyl)diphenylmethyl]), PMP (p-methoxybenzyl ether), PIV (tert-valeryl), THP (tetrahydropyranyl), THF (tetrahydrofuran) and trityl (triphenylmethyl, Tr); and

[0117] X is halogen).

[0118] As shown in step 1 of reaction formula 2, the amine of the compound shown in formula 2a reacts with Cl of the compound shown in formula 3 to prepare the compound shown in formula 4, wherein an amide bond is formed. The above steps can be performed using methods known to those skilled in the art, and the compound can be prepared according to embodiments of the present invention, but this is only an example and is not limited thereto.

[0119] Step 2 of reaction formula 2 is a step of preparing the alcohol compound shown in formula 1a by removing the alcohol protecting group of the compound shown in formula 4, which can be carried out according to a known method capable of removing the alcohol protecting group, and those skilled in the art can easily select and carry out the conditions under which the removal reaction can be carried out according to the type of the protecting group. The compound can be prepared according to an embodiment of the present invention, but this is only an example and is not limited thereto.

[0120] Step 3 of Scheme 2 is a step of preparing a compound represented by Formula 1b by reacting a hydroxyl group of a compound represented by Formula 1a with a halide of a compound represented by Formula 4. The above step can be performed using a method known to those skilled in the art, and the compound can be prepared according to an embodiment of the present invention, but this is merely an example and is not limited thereto.

[0121] In another aspect of the present invention, the present invention provides a pharmaceutical composition comprising a compound represented by Formula 1, an isomer thereof, a solvate thereof, a hydrate thereof or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating an autoimmune disease.

[0122] This compound can inhibit monocyte adhesion to intestinal epithelial cells via TNF-α or IL-6.

[0123] The autoimmune disease may be selected from at least one of the following: inflammatory bowel disease, asthma, type 1 diabetes, rheumatoid arthritis, polymyalgia rheumatica, ankylosing spondylitis, psoriatic arthritis, psoriasis, eczema, sclerosis, vitiligo, multiple sclerosis, IL-17-induced dementia, peripheral neuritis, uveitis, polymyositis / dermatomyositis, autoimmune cytopenia, autoimmune myocarditis, atopic dermatitis, primary cirrhosis, dry eye syndrome, fibromyalgia, Goodpasture's syndrome syndrome), autoimmune meningitis, Sjögren's syndrome, systemic lupus erythematosus, Addison's disease, alopecia areata, autoimmune hepatitis, autoimmune parotitis, dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, celiac disease, Guillain-Barré syndrome, Hashimoto's disease, hemolytic anemia, myasthenia gravis, amyotrophic lateral sclerosis, pemphigus vulgaris, rheumatic fever, sarcoidosis, sclerosis cutis, spondyloarthritis, thyroiditis, vasculitis, vitiligo, myxedema, pernicious anemia, antiphospholipid syndrome, late and chronic rejection of solid organ transplantation, and graft-versus-host disease.

[0124] The inflammatory bowel disease may be any one selected from the group consisting of enteritis, colitis, ulcerative enteritis, Crohn's disease, Crohn's cell tumor, irritable bowel syndrome, bleeding rectal ulcer, pouchitis, peptic ulcer, intestinal Behcet's disease, and gastritis.

[0125] In the pharmaceutical composition of the present invention, the compound shown in Formula 1 or its pharmaceutically acceptable salt can be administered orally or parenterally, preferably parenterally, and can be used in the general form of a pharmaceutical preparation. That is, the compound or its pharmaceutically acceptable salt can be prepared into a preparation for oral or parenteral administration by mixing with commonly used diluents or excipients such as fillers, fillers, adhesives, wetting agents, disintegrants and surfactants. Solid preparations for oral administration are tablets, pills, powders, granules and capsules. These solid preparations are prepared by mixing one or more compounds with one or more suitable excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate, talc, etc. can be used. Liquid preparations for oral administration are suspensions, solutions, emulsions and syrups, and the above-mentioned preparations can also contain various excipients such as wetting agents, sweeteners, aromatics and preservatives in addition to commonly used simple diluents such as water and liquid paraffin. Preparations for parenteral administration are sterile aqueous solutions, water-insoluble excipients, suspensions and emulsions. In addition to the active compound, water-insoluble excipients and suspensions may contain propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like.

[0126] The pharmaceutical composition comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient can be administered parenterally, including subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection.

[0127] At this time, in order to prepare a compound shown in Formula 1 or a pharmaceutically acceptable salt thereof for a preparation for parenteral administration, the compound shown in Formula 1 or a pharmaceutically acceptable salt thereof is mixed with a stabilizer or a buffer in water to prepare a solution or suspension, which is then formulated into an ampoule or a vial. The composition herein may be sterile and additionally contain a preservative, a stabilizer, a wettable powder or an emulsifier, a salt and / or a buffer for adjusting osmotic pressure, and other therapeutically useful substances, and the composition may be formulated by conventional mixing, granulation or coating methods.

[0128] Examples of preparations for oral administration include tablets, pills, hard / soft capsules, solutions, suspensions, emulsions, syrups, granules, elixirs and lozenges, etc. These preparations can also include diluents (e.g., lactose, glucose, sucrose, mannitol, sorbitol, cellulose and / or glycine) and lubricants (e.g., silicon dioxide, talc, stearates and their magnesium or calcium salts and / or polyethylene glycol) in addition to the active ingredient. Tablets can include binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinyl pyrrolidone, and if necessary, can also include disintegrants such as starch, agarose, alginic acid or its sodium salt or azeotropic mixture and / or absorbents, colorants, flavors and sweeteners.

[0129] In another aspect of the present invention, the present invention provides a health functional food, which comprises the compound represented by Formula 1, its isomer, its solvate, its hydrate or its pharmaceutically acceptable salt as an active ingredient for preventing or improving autoimmune diseases.

[0130] In another aspect of the present invention, the present invention provides a method for preventing or treating an autoimmune disease, the method comprising the step of administering a pharmaceutical composition or a health functional food to a subject in need thereof, wherein the pharmaceutical composition or the health functional food comprises a compound represented by Formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.

[0131] In another aspect of the present invention, the present invention provides the use of the pharmaceutical composition or health functional food for preventing or treating autoimmune diseases, wherein the pharmaceutical composition or health functional food comprises the compound represented by Formula 1, its isomer, its solvate, its hydrate or its pharmaceutically acceptable salt as an active ingredient.

[0132] Hereinafter, the present invention will be described in detail through examples and experimental examples.

[0133] However, the following examples and experimental examples are only used to illustrate the present invention, and the contents of the present invention are not limited thereto.

[0134] <Preparation Example 1> Preparation of 5-(Benzyloxy)-3,4,6-trimethylpyridin-2-amine

[0135]

[0136] Step 1: Synthesis of 4,5-bis(chloromethyl)-2-methylpyridin-3-ol hydrochloride (Formula II)

[0137] SOCl 2 (15 mL) and DMF (0.38 mL) were added to pyridoxine hydrochloride (Formula I) (10 g), and the mixture was stirred at 80° C. for 30 minutes. The reaction mixture was cooled to room temperature, and Et 2 O (140 mL), and the mixture was stirred under ice cooling for 1 hour. The precipitated solid in the reaction solution was filtered under reduced pressure, and the filtered solid was washed with Et 2 O and dried to give the target compound II (11.3 g) as a white solid.

[0138] 1 H-NMR ((CD 3 ) 2 SO)δ8.42(s,1H),4.99(s,2H),4.96(s,2H),2.63(s,3H).

[0139] Step 2: Synthesis of 2,4,5-trimethylpyridin-3-ol (Formula III)

[0140] Zinc powder (8.08 g) was added to a suspension of compound II (10 g) in acetic acid (50 mL) in small portions several times, and the mixture was stirred under reflux at 130° C. for 2 hours. The reaction mixture was cooled to room temperature, and the solid in the reaction solution was removed by filtration under reduced pressure. Then, the pH of the filtrate was adjusted to 6 with a 10 M NaOH solution. The filtrate was saturated with salt and then extracted several times with EtOAc. The extract was washed with saturated brine and filtered through anhydrous MgSO 4 The residue was purified by column chromatography (CHCl 3 :MeOH=20:1) to obtain the target compound III (5.2 g) as a white solid.

[0141] 1 H-NMR ((CD 3 ) 2SO)δ8.49(s,1H),7.72(s,1H),2.31(s,3H),2.12(s,3H),2.08(s,3H).

[0142] Step 3: Synthesis of 6-bromo-2,4,5-trimethylpyridin-3-ol (Formula IV)

[0143] 1,3-Dibromo-5,5-dimethylhydantoin (DBDMH, 2.5 g) was added to a THF suspension (30 mL) of compound III (2.5 g), and then stirred at room temperature for 3 hours. After the reaction mixture was concentrated, the residue was diluted with EtOAc and water, and the aqueous layer was extracted with EtOAc. The EtOAc solution was washed with saturated brine and filtered through anhydrous MgSO 4 Dry, filter, and concentrate under reduced pressure.The residue was purified by column chromatography (EtOAc:hexane=1:4) to give the target compound IV (3.22 g) as a light yellow solid.

[0144] 1 H-NMR (CDCl 3 )δ5.56(br s,1H),2.42(s,3H),2.31(s,3H),2.25(s,3H).

[0145] Step 4: Synthesis of 3-(benzyloxy)-6-bromo-2,4,5-trimethylpyridine (Formula V)

[0146] To a DMF solution (15 mL) of compound IV (6.5 g) were added K 2 CO 3 (20.78 g) and benzyl chloride (5.2 mL), and then stirred at room temperature for 12 hours. The reaction solution was diluted with EtOAc and washed several times with a small amount of water. The EtOAc solution was washed with saturated brine and filtered through anhydrous MgSO 4 Dry, filter, and concentrate under reduced pressure. The residue was purified by column chromatography (EtOAc:hexane=1:20) to obtain the target compound V (8.9 g) as a white solid.

[0147] 1 H-NMR (CDCl 3 )δ7.38-7.43(m,5H),4.77(s,2H),2.46(s,3H),2.32(s,3H),2.24(s,3H).

[0148] Step 5: Synthesis of 5-(benzyloxy)-N-(diphenylmethylene)-3,4,6-trimethylpyridin-2-amine (Formula VI)

[0149] Benzophenoneimine (1.73 mL) was added to compound V (3 g), tris(dibenzylideneacetone)dipalladium(0) (203 mg), 2,2'-bis(diphenylphosphine)-1,1'-binaphthyl (249 mg) and NaO t Bu (1.36 g) was added to a toluene (30 mL) solution and the mixture was stirred under reflux for 12 h. The reaction solution was cooled to room temperature and diluted with EtOAc and water. The EtOAc solution was washed several times with saturated brine and filtered through anhydrous MgSO 4 Dry, filter, and concentrate under reduced pressure.The residue was purified by column chromatography (EtOAc:hexane=1:4) to give the target compound VI (3.28 g) as a yellow solid.

[0150] 1 H-NMR (CDCl 3 )δ7.80(d,J=7.1Hz,2H),7.17-7.48(m,13H),4.69(s,2H),2.29(s,3H),2.03(s,3H),1.91(s,3H).

[0151] Step 6: Synthesis of 5-(benzyloxy)-3,4,6-trimethylpyridin-2-amine (Formula VII)

[0152] Under ice cooling, acetyl chloride (3.2 mL) was gradually added to a solution of methanol (20 mL) in a mixture of compound VI (7.7 g) in methanol (60 mL)-THF (20 mL), and then stirred at room temperature for 12 hours. After the reaction solution was concentrated under reduced pressure, the residue was diluted with EtOAc and washed several times with a saturated sodium bicarbonate solution. The EtOAc solution was washed with saturated brine and filtered through anhydrous MgSO 4 The residue was purified by column chromatography (CHCl 3 :MeOH=20:1) to obtain the target compound VII (4.36 g) as a light yellow solid.

[0153] 1 H-NMR (CDCl 3 )δ7.31-7.45(m,5H),4.68(s,2H),4.25(br s,1H),2.34(s,3H),2.16(s,3H),1.99(s,3H).

[0154] <General Preparation Process 1 of Example>

[0155] The compounds of Examples 1-26 (Compounds IX-01 to IX-26) were prepared according to the preparation method of Reaction Formula A.

[0156] [Reaction formula A]

[0157]

[0158] In the above reaction formula A,

[0159] A.R 1 , R 2 , R 3 , R 4 and R 5 As defined in this specification.

[0160] Specifically, at room temperature, compound VIII (1.5-2.0 mmol) and Et 3 N (2.0 mmol) was added successively to the CH 2 Cl 2 (or ClCH 2 CH 2 Cl, 10 mL) solution, and the reaction mixture was stirred at room temperature to 60°C until compound VII disappeared on TLC. 2 Cl 2 The reaction mixture was diluted and washed with saturated NaHCO 3 Wash with aqueous solution. 2 Cl 2 The solution was passed through anhydrous MgSO 4 After drying, filtering and concentration under reduced pressure, the residue was purified by silica gel column chromatography to give compounds IX-01 to IX-26.

[0161] <Example 1> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide (Formula IX-01)

[0162] The target compound was prepared according to the method of general preparation process 1 of the example.

[0163] 1 H-NMR (CDCl 3 )δ9.69(s,1H),8.75(s,1H),7.67(d,J=7.9Hz,1H),7.52-7.27(m,7H),7.19-7.08(m,2H),4.80(s,2H),2.47(s,3H),2.31(s,3H),2.23(s,3H).

[0164] <Example 2> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-1-methyl-1H-indole-2-carboxamide (Formula IX-02)

[0165] The target compound was prepared according to the method of general preparation process 1 of the example.

[0166] 1 H-NMR (CDCl 3 )δ8.34(s,1H),7.68(d,J=8.0Hz,1H),7.51-7.32(m,7H),7.15(d,J=0.5H z,2H),4.80(s,2H),4.06(s,3H),2.47(s,3H),2.30(s,3H),2.23(s,3H).

[0167] <Example 3> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-7-bromo-1H-indole-2-carboxamide (Formula IX-03)

[0168] The target compound was prepared according to the method of general preparation process 1 of the example.

[0169] 1 H-NMR (CDCl 3 )δ9.45(s,2H),7.60(d,J=8.0Hz,1H),7.51-7.33(m,6H),7.21(s,1H),7. 04(d,J=7.8Hz,1H),4.77(s,2H),2.45(s,3H),2.26(s,3H),2.22(s,3H).

[0170] <Example 4> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-6-chloro-1H-indole-2-carboxamide (Formula IX-04)

[0171] The target compound was prepared according to the method of general preparation process 1 of the example.

[0172] 1 H-NMR ((CD 3 ) 2 SO)δ11.84(s,1H),10.51(s,1H),7.69(d,J=8.5Hz,1H),7.56-7.35(m,7H),7. 08(dd,J=8.5,1.9Hz,1H),4.85(s,2H),2.40(s,3H),2.26(s,3H),2.08(s,3H).

[0173] <Example 5> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-6-bromo-1H-indole-2-carboxamide (Formula IX-05)

[0174] The target compound was prepared according to the method of general preparation process 1 of the example.

[0175] 1 H-NMR ((CD 3 ) 2 SO)δ11.84(s,1H),10.52(s,1H),7.65(d,J=10.3Hz,2H),7.58-7.35(m,6H),7. 20(dd,J=8.4,1.2Hz,1H),4.86(s,2H),2.40(s,3H),2.27(s,3H),2.09(s,3H).

[0176] <Example 6> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-fluoro-1H-indole-2-carboxamide (Formula IX-06)

[0177] The target compound was prepared according to the method of general preparation process 1 of the example.

[0178] 1 H-NMR (CDCl 3 )δ9.66(s,1H),8.64(s,1H),7.52-7.37(m,5H),7.30(dd,J=6.6,2.8Hz,2H ),7.09-6.99(m,2H),4.81(s,2H),2.46(s,3H),2.30(s,3H),2.22(s,3H).

[0179] <Example 7> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-bromo-1H-indole-2-carboxamide (Formula IX-07)

[0180] The target compound was prepared according to the method of general preparation process 1 of the example.

[0181] 1 H-NMR (CDCl 3 )δ9.93(s,1H),7.80(d,J=1.7Hz,1H),7.50-7.37(m,6H),7.35(d,J=1.8Hz,1H),7. 30(s,1H),7.06(d,J=1.4Hz,1H),4.75(s,2H),2.48(s,3H),2.21(d,J=8.1Hz,6H).

[0182] <Example 8> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-chloro-1H-indole-2-carboxamide (Formula IX-08)

[0183] The target compound was prepared according to the method of general preparation process 1 of the example.

[0184] 1 H-NMR (CDCl 3 )δ10.25(s,1H),9.18(dd,J=5.2,2.9Hz,1H),7.58(s,1H),7.43(dd,J=11.2,5.4Hz,5H), 7.19(d,J=2.6Hz,2H),7.02(s,1H),4.81(s,2H),2.45(s,3H),2.30(s,3H),2.23(s,3H).

[0185] <Example 9> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-methyl-1H-indole-2-carboxamide (Formula IX-09)

[0186] The target compound was prepared according to the method of general preparation process 1 of the example.

[0187] 1 H-NMR (CDCl 3 )δ12.72(s,1H),11.04(s,1H),10.37(s,1H),7.84(s,1H),7.55-7.35(m,7H),7.20 (d,J=8.4Hz,1H),4.84(s,2H),2.55(s,3H),2.52(s,3H),2.31(s,3H),2.25(s,3H).

[0188] <Example 10> Synthesis of N-(5-(benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethyl)-1H-indole-2-carboxamide (Formula IX-10)

[0189] The target compound was prepared according to the method of general preparation process 1 of the example.

[0190] 1 H-NMR (CDCl 3 )δ10.26(s,1H),9.16(s,1H),7.94(s,1H),7.53-7.33(m,7H),7.17(d,J=1.3Hz,1H),4.83(s,2H),2.46(s,3H),2.32(s,3H),2.24(s,3H).

[0191] <Example 11> Synthesis of N-(5-(benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethoxy)-1H-indole-2-carboxamide (Formula IX-11)

[0192] The target compound was prepared according to the method of general preparation process 1 of the example.

[0193] 1 H-NMR (CDCl 3 )δ10.06(s,1H),9.03(s,1H),7.53-7.28(m,7H),7.12(d,J=11.8Hz,2H),4.82(s,2H),2.46(s,3H),2.31(s,3H),2.23(s,3H).

[0194] <Example 12> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-6-methoxy-1H-indole-2-carboxamide (Formula IX-12)

[0195] The target compound was prepared according to the method of general preparation process 1 of the example.

[0196] 1 H-NMR (CDCl 3 )δ9.54(s,1H),8.76-8.54(m,1H),7.56-7.35(m,6H),7.03(d,J=1.8Hz,1H),6.81(dd ,J=4.6,2.4Hz,2H),4.79(s,2H),3.83(s,3H),2.45(s,3H),2.28(s,3H),2.22(s,3H).

[0197] <Example 13> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-methoxy-1H-indole-2-carboxamide (Formula IX-13)

[0198] The target compound was prepared according to the method of general preparation process 1 of the example.

[0199] 1 H-NMR (CDCl 3 )δ9.72(s,1H),9.24-8.76(m,1H),7.54-7.33(m,5H),7.23(s,1H),7.04(s,2H),6. 98-6.89(m,1H),4.78(s,2H),3.83(s,3H),2.46(s,3H),2.28(s,3H),2.22(s,3H).

[0200] <Example 14> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5,6-dimethoxy-1H-indole-2-carboxamide (Formula IX-14)

[0201] The target compound was prepared according to the method of general preparation process 1 of the example.

[0202] 1 H-NMR (CDCl 3 )δ9.57(s,1H),7.41(dd,J=8.6,3.9Hz,5H),7.02(s,2H),6.84(s,1H),4.73(s,2H),3.91(s,6H),2.47(s,3H),2.22(d,J=4.8Hz,6H).

[0203] <Example 15> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide (Formula IX-15)

[0204] The target compound was prepared according to the method of general preparation process 1 of the example.

[0205] 1 H-NMR (CDCl 3 )δ8.60(s,1H),7.70(d,J=7.7Hz,1H),7.59(d,J=0.8Hz,1H),7.57-7.28(m,8H),4.81(s,2H),2.47(s,3H),2.30(s,3H),2.23(s,3H).

[0206] <Example 16> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-chlorobenzofuran-2-carboxamide (Formula IX-16)

[0207] The target compound was prepared according to the method of general preparation process 1 of the example.

[0208] 1 H-NMR (CDCl 3 )δ8.64(s,1H),7.70-7.64(m,1H),7.52(d,J=0.8Hz,1H),7.50-7.36(m,7H),4.81(s,2H),2.46(s,3H),2.30(s,3H),2.22(s,3H).

[0209] <Example 17> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-bromobenzofuran-2-carboxamide (Formula IX-17)

[0210] [N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-5-bromobenzofuran-2-carboxamide]

[0211] The target compound was prepared according to the method of general preparation process 1 of the example.

[0212] 1 H-NMR (CDCl 3 )δ8.70(s,1H),7.85(d,J=1.9Hz,1H),7.54(d,J=3.3Hz,2H),7.50-7.38(m,6H),4.81(s,2H),2.47(s,3H),2.31(s,3H),2.22(s,3H).

[0213] <Example 18> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-7-methoxybenzofuran-2-carboxamide (Formula IX-18)

[0214] The target compound was prepared according to the method of general preparation process 1 of the example.

[0215] 1 H-NMR (CDCl 3 )δ8.98(s,1H),7.66-7.59(m,1H),7.51-7.33(m,5H),7.25-7.22(m,2H),6.94(dd,J=7.3 ,1.6Hz,1H),4.81(s,2H),4.03(s,3H),2.49(s,3H),2.31(d,J=2.3Hz,3H),2.22(s,3H).

[0216] <Example 19> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-methylbenzofuran-2-carboxamide (Formula IX-19)

[0217] The target compound was prepared according to the method of general preparation process 1 of the example.

[0218] 1 H-NMR (CDCl 3 )δ8.59(s,1H),7.63(d,J=7.9Hz,1H),7.56-7.27(m,8H),4.81(s,2H),2.64(s,3H),2.48(s,3H),2.27(d,J=10.2Hz,6H).

[0219] <Example 20> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide (Formula IX-20)

[0220] The target compound was prepared according to the method of general preparation process 1 of the example.

[0221] 1 H-NMR (CDCl 3 )δ8.69(s,1H),7.97(s,1H),7.90-7.82(m,2H),7.51-7.35(m,7H),4.80(s,2H),2.44(s,3H),2.29(s,3H),2.23(s,3H).

[0222] <Example 21> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-chlorobenzo[b]thiophene-2-carboxamide (Formula IX-21)

[0223] The target compound was prepared according to the method of general preparation process 1 of the example.

[0224] 1 H-NMR (CDCl 3 )δ8.87(s,1H),7.97-7.90(m,1H),7.85(dt,J=5.2,3.3Hz,1H),7.54-7.39(m,7H),4.81(s,2H),2.48(s,3H),2.29(s,3H),2.24(s,3H).

[0225] <Example 22> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-bromobenzo[b]thiophene-2-carboxamide (Formula IX-22)

[0226] The target compound was prepared according to the method of general preparation process 1 of the example.

[0227] 1 H-NMR (CDCl 3 )δ8.89(s,1H),7.97-7.82(m,2H),7.56-7.38(m,7H),4.81(s,2H),2.47(s,3H),2.30(s,3H),2.25(s,3H).

[0228] <Example 23> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-chloro-6-methylbenzo[b]thiophene-2-carboxamide (Formula IX-23)

[0229] The target compound was prepared according to the method of general preparation process 1 of the example.

[0230] 1 H-NMR (CDCl 3)δ10.27(s,1H),8.65(s,1H),8.34(d,J=1.6Hz,1H),7.91(d,J=8.7Hz,1H),7.63(dd,J=8.7,1.9Hz,1H),2.32(s,3H),2.18(s,3H),2.10(s,3H).

[0231] <Example 24> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-chloro-6-fluorobenzo[b]thiophene-2-carboxamide (Formula IX-24)

[0232] The target compound was prepared according to the method of general preparation process 1 of the example.

[0233] 1 H-NMR (CDCl 3 )δ8.84(s,1H),7.89(dd,J=9.0,5.0Hz,1H),7.58-7.50(m,1H),7.49-7.33(m ,5H),7.32-7.27(m,1H),4.81(s,2H),2.47(s,3H),2.30(s,3H),2.24(s,3H).

[0234] <Example 25> Synthesis of N-(5-(benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3,6-dichlorobenzo[b]thiophene-2-carboxamide (Formula IX-25)

[0235] The target compound was prepared according to the method of general preparation process 1 of the example.

[0236] 1 H-NMR (CDCl 3 )δ8.97-8.61(m,1H),7.84(dd,J=5.2,3.4Hz,2H),7.53-7.34(m,6H),4.81(s,6H),2.46(s,3H),2.29(s,3H),2.24(s,3H).

[0237] <Example 26> Synthesis of N-(5-(Benzyloxy)-3,4,6-trimethylpyridin-2-yl)-3-chloro-6-methoxybenzo[b]thiophene-2-carboxamide (Formula IX-26)

[0238] The target compound was prepared according to the method of general preparation process 1 of the example.

[0239] 1 H-NMR (CDCl 3)δ8.77(s,1H),7.79(d,J=9.0Hz,1H),7.53-7.33(m,5H),7.12(dd,J=9.0,2 .3Hz,1H),4.81(s,2H),3.91(s,3H),2.47(s,3H),2.29(s,3H),2.23(s,3H).

[0240] <General Preparation Process 2 of Example>

[0241] The compounds of Examples 27-52 (Compounds X-01 to X-26) were prepared according to the preparation method of the following reaction formula B.

[0242] [Reaction formula B]

[0243]

[0244] In the above reaction formula B,

[0245] A.R 1 , R 2 , R 3 , R 4 and R 5 As defined in this specification.

[0246] Pentamethylbenzene (3.0 mmol) was added to the CH 2 Cl 2 (10 mL), and the reaction solution was cooled with ice. 1 M BCl 3 CH 2 Cl 2 The reaction mixture was stirred under ice cooling until compound IX disappeared from TLC. 10 mL of CHCl was added to the reaction solution. 3 The mixture was stirred at room temperature for 30 minutes and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compounds X-01 to X-26.

[0247] <Example 27> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide (Formula X-01)

[0248] The target compound was prepared according to the method of general preparation process 2 of the example.

[0249] 1 H-NMR ((CD 3 ) 2SO)δ11.64(s,1H),10.24(s,1H),8.60(s,1H),7.64(d,J=8.0Hz,1H),7.45(d,J=8.2Hz,1H),7.3 6(d,J=1.4Hz,1H),7.31-7.13(m,1H),7.10-6.99(m,1H),2.35(s,3H),2.18(s,3H),2.05(s,3H).

[0250] <Example 28> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1-methyl-1H-indole-2-carboxamide (Formula X-02)

[0251] The target compound was prepared according to the method of general preparation process 2 of the example.

[0252] 1 H-NMR ((CD 3 ) 2 SO)δ10.18(s,1H),8.56(s,1H),7.67(d,J=7.9Hz,1H),7.55(d,J=8.4Hz,1H),7.34-7.25( m,2H),7.13(dd,J=11.0,3.9Hz,1H),4.00(s,3H),2.35(s,3H),2.18(s,3H),2.07(s,3H).

[0253] <Example 29> Synthesis of 7-bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide (Formula X-03)

[0254] The target compound was prepared according to the method of general preparation process 2 of the example.

[0255] 1 H-NMR ((CD 3 ) 2 SO)δ11.62(s,1H),10.64(d,J=0.8Hz,1H),9.09-8.86(m,1H),7.70(d,J=7.9Hz,1H),7.4 6(dd,J=14.5,4.5Hz,2H),7.04(t,J=7.8Hz,1H),2.39(s,3H),2.22(s,3H),2.09(s,3H).

[0256] <Example 30> Synthesis of 6-chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide (Formula X-04)

[0257] The target compound was prepared according to the method of general preparation process 2 of the example.

[0258] 1 H-NMR ((CD 3 ) 2 SO)δ11.83(s,1H),10.36(s,1H),8.65(s,1H),7.68(d,J=8.5Hz,1H),7.42(d,J= 14.2Hz,2H),7.07(dd,J=8.5,1.6Hz,1H),2.34(s,3H),2.17(s,3H),2.03(s,3H).

[0259] <Example 31> Synthesis of 6-bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide (Formula X-05)

[0260] The target compound was prepared according to the method of general preparation process 2 of the example.

[0261] 1 H-NMR ((CD 3 ) 2 SO)δ11.79(s,1H),10.32(s,1H),8.62(s,1H),7.63(d,J=8.7Hz,2H),7.38(d,J= 1.3Hz,1H),7.18(dd,J=8.5,1.8Hz,1H),2.35(s,3H),2.18(s,3H),2.04(s,3H).

[0262] <Example 32> Synthesis of 5-fluoro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide (Formula X-06)

[0263] The target compound was prepared according to the method of general preparation process 2 of the example.

[0264] 1 H-NMR ((CD 3 ) 2 SO)δ11.77(s,1H),10.30(s,1H),8.62(s,1H),7.43(dt,J=6.6,3.0Hz,2H),7.35(d ,J=1.5Hz,1H),7.07(td,J=9.4,2.5Hz,1H),2.35(s,3H),2.18(s,3H),2.04(s,3H).

[0265] <Example 33> Synthesis of 5-bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide (Formula X-07)

[0266] The target compound was prepared according to the method of general preparation process 2 of the example.

[0267] 1 H-NMR ((CD 3 ) 2 SO)δ11.85(s,1H),10.31(s,1H),8.61(s,1H),7.87(d,J=1.2Hz,1H),7.35(dd,J=9.5,7.8Hz,3H),2.35(s,3H),2.18(s,3H),2.05(s,3H).

[0268] <Example 34> Synthesis of 5-chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide (Formula X-08)

[0269] The target compound was prepared according to the method of general preparation process 2 of the example.

[0270] 1 H-NMR ((CD 3 ) 2 SO)δ11.90(s,1H),10.37(s,1H),8.67(s,1H),7.73(d,J=1.8Hz,1H),7.44(d,J=8.8Hz ,1H),7.35(s,1H),7.20(dd,J=8.8,2.0Hz,1H),2.34(s,3H),2.17(s,3H),2.04(s,3H).

[0271] <Example 35> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-methyl-1H-indole-2-carboxamide (Formula X-09)

[0272] The target compound was prepared according to the method of general preparation process 2 of the example.

[0273] 1 H-NMR ((CD 3 ) 2SO)δ11.54(d,J=1.1Hz,1H),10.22(s,1H),8.63(s,1H),7.41(s,1H),7.30(dd,J=12.6,4 .9Hz,2H),7.03(dd,J=8.4,1.4Hz,1H),2.36(d,J=8.1Hz,6H),2.17(s,3H),2.04(s,3H).

[0274] <Example 36> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethyl)-1H-indole-2-carboxamide (Formula X-10)

[0275] The target compound was prepared according to the method of general preparation process 2 of the example.

[0276] 1 H-NMR ((CD 3 ) 2 SO)δ12.13(s,1H),10.44(s,1H),8.64(s,1H),8.10(s,1H),7.62(d,J=8.7Hz,1H),7.59-7.44(m,2H),2.35(s,3H),2.18(s,3H),2.05(s,3H).

[0277] <Example 37> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethoxy)-1H-indole-2-carboxamide (Formula X-11)

[0278] The target compound was prepared according to the method of general preparation process 2 of the example.

[0279] 1 H-NMR ((CD 3 ) 2 SO)δ12.08(s,1H),10.74(s,1H),9.31(s,1H),7.71(s,1H),7.53(d,J=9.2Hz,2H),7.21(d,J=8.8Hz,1H),2.44(s,3H),2.26(s,3H),2.11(s,3H).

[0280] <Example 38> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-6-methoxy-1H-indole-2-carboxamide (Formula X-12)

[0281] The target compound was prepared according to the method of general preparation process 2 of the example.

[0282] 1 H-NMR ((CD3 ) 2 SO)δ11.42(s,1H),10.07(s,1H),8.54(s,1H),7.51(d,J=8.7Hz,1H),7.28(s,1H),6.90( s,1H),6.71(dd,J=8.7,2.3Hz,1H),3.78(s,3H),2.34(s,3H),2.18(s,3H),2.04(s,3H).

[0283] <Example 39> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-methoxy-1H-indole-2-carboxamide (Formula X-13)

[0284] The target compound was prepared according to the method of general preparation process 2 of the example.

[0285] 1 H-NMR ((CD 3 ) 2 SO)δ11.85(s,1H),10.31(s,1H),8.61(s,1H),7.87(d,J=1.2Hz,1H),7.35(dd,J=9.5,7.8Hz,3H),2.35(s,3H),2.18(s,3H),2.05(s,3H).

[0286] <Example 40> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5,6-dimethoxy-1H-indole-2-carboxamide (Formula X-14)

[0287] The target compound was prepared according to the method of general preparation process 2 of the example.

[0288] 1 H-NMR ((CD 3 ) 2 SO)δ11.33(s,1H),10.04(s,1H),8.55(s,1H),7.24(d,J=1.7Hz,1H),7.09 (s,1H),6.90(s,1H),3.77(s,6H),2.34(s,3H),2.17(s,3H),2.04(s,3H).

[0289] <Example 41> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide (Formula X-15)

[0290] The target compound was prepared according to the method of general preparation process 2 of the example.

[0291] 1 H-NMR ((CD 3 ) 2 SO)δ10.44(s,1H),8.66(s,1H),7.81(d,J=7.7Hz,1H),7.76-7.65(m,2H),7.5 3-7.45(m,1H),7.35(t,J=7.5Hz,1H),2.34(s,3H),2.17(s,3H),2.04(s,3H).

[0292] <Example 42> Synthesis of 5-chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide (Formula X-16)

[0293] The target compound was prepared according to the method of general preparation process 2 of the example.

[0294] 1 H-NMR ((CD 3 ) 2 SO)δ10.75(s,1H),9.28-9.04(m,1H),7.93(d,J=2.2Hz,1H),7.75(d,J=9.2 Hz,2H),7.53(dd,J=8.7,2.2Hz,2H),2.41(s,3H),2.24(s,3H),2.10(s,3H).

[0295] <Example 43> Synthesis of 5-bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide (Formula X-17)

[0296] The target compound was prepared according to the method of general preparation process 2 of the example.

[0297] 1 H-NMR ((CD 3 ) 2 SO)δ10.44(s,1H),8.66(s,1H),7.81(d,J=7.7Hz,1H),7.76-7.65(m,2H),7.5 3-7.45(m,1H),7.35(t,J=7.5Hz,1H),2.34(s,3H),2.17(s,3H),2.04(s,3H).

[0298] <Example 44> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-7-methoxybenzofuran-2-carboxamide (Formula X-18)

[0299] The target compound was prepared according to the method of general preparation process 2 of the example.

[0300] 1 H-NMR ((CD 3 ) 2 SO)δ10.53(s,1H),8.90(d,J=2.5Hz,1H),7.76(s,1H),7.40-7.22(m,2H), 7.09(d,J=7.6Hz,1H),3.98(s,3H),2.37(s,3H),2.20(s,3H),2.07(s,3H).

[0301] <Example 45> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-3-methylbenzofuran-2-carboxamide (Formula X-19)

[0302] The target compound was prepared according to the method of general preparation process 2 of the example.

[0303] 1 H-NMR ((CD 3 ) 2 SO)δ10.10(s,1H),8.58(s,1H),7.77(d,J=7.7Hz,1H),7.62(d,J=8.2Hz,1H),7.55- 7.46(m,1H),7.41-7.33(m,1H),2.55(s,3H),2.33(s,3H),2.17(s,3H),2.06(s,3H).

[0304] <Example 46> Synthesis of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide (Formula X-20)

[0305] The target compound was prepared according to the method of general preparation process 2 of the example.

[0306] 1 H-NMR ((CD 3 ) 2 SO)δ11.33(s,1H),10.17-9.79(m,1H),8.55(s,1H),8.04(dd,J=14.2,7.7Hz,2H),7.62-7.38(m,2H),2.53(s,3H),2.33(s,3H),2.20(s,3H).

[0307] <Example 47> Synthesis of 3-chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide (Formula X-21)

[0308] The target compound was prepared according to the method of general preparation process 2 of the example.

[0309] 1 H-NMR ((CD 3 ) 2 SO)δ10.26(s,1H),8.67(s,1H),8.13(dd,J=6.2,3.0Hz,1H),7.92(dd,J=6.3,3 .0Hz,1H),7.61(dd,J=6.1,3.2Hz,2H),2.33(s,3H),2.18(s,3H),2.11(s,3H).

[0310] <Example 48> Synthesis of 3-bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide (Formula X-22)

[0311] The target compound was prepared according to the method of general preparation process 2 of the example.

[0312] 1 H-NMR ((CD 3 ) 2 SO)δ10.37(s,1H),8.63(s,1H),8.19-8.09(m,1H),7.94-7.84(m,1H),7.60(dd,J=6.1,3.1Hz,2H),2.33(s,3H),2.18(s,3H),2.12(s,3H).

[0313] <Example 49> Synthesis of 3-chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-6-methylbenzo[b]thiophene-2-carboxamide (Formula X-23)

[0314] The target compound was prepared according to the method of general preparation process 2 of the example.

[0315] 1 H-NMR ((CD 3 ) 2 SO)δ10.16(s,1H),8.64(s,1H),7.92(s,1H),7.81(d,J=8.3Hz,1H),7.44( dd,J=8.3,0.9Hz,1H),3.32(s,3H),2.34(s,3H),2.19(s,3H),2.12(s,3H).

[0316] <Example 50> Synthesis of 3-chloro-6-fluoro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide (Formula X-24)

[0317] The target compound was prepared according to the method of general preparation process 2 of the example.

[0318] 1 H-NMR ((CD 3 ) 2 SO)δ10.40(s,1H),9.12(s,1H),8.10(dd,J=9.1,2.3Hz,1H),7.96(dd,J=9.0,5 .1Hz,1H),7.49(td,J=9.0,2.4Hz,1H),2.40(s,3H),2.23(s,3H),2.14(s,3H).

[0319] <Example 51> Synthesis of 3,6-dichloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide (Formula X-25)

[0320] The target compound was prepared according to the method of general preparation process 2 of the example.

[0321] 1 H-NMR ((CD 3 ) 2 SO)δ10.27(s,1H),8.65(s,1H),8.34(d,J=1.6Hz,1H),7.91(d,J=8.7Hz,1H),7.63(dd,J=8.7,1.9Hz,1H),2.32(s,3H),2.18(s,3H),2.10(s,3H).

[0322] <Example 52> Synthesis of 3-chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-6-methoxybenzo[b]thiophene-2-carboxamide (Formula X-26)

[0323] The target compound was prepared according to the method of general preparation process 2 of the example.

[0324] 1 H-NMR ((CD 3 ) 2 SO)δ10.16(s,1H),8.64(s,1H),7.92(s,1H),7.81(d,J=8.3Hz,1H),7.44( dd,J=8.3,0.9Hz,1H),3.32(s,3H),2.34(s,3H),2.19(s,3H),2.12(s,3H).

[0325] <Example 53> Synthesis of 3-chloro-6-fluoro-N-(5-methoxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide (Formula XI-01)

[0326] A 1:1 mixed solvent of THF and water (2 mL) was added to compound X-24 (20 mg), and K 2 CO 3 (76 mg) and CH 3 I (34 μL). The reaction mixture was stirred at room temperature for 24 hours and then concentrated under reduced pressure. 2 Cl 2 The residue was diluted with water and washed with CH 2 Cl 2 The aqueous layer was extracted several times. 2 Cl 2 The solution was passed through anhydrous MgSO 4 The residue was purified by silica gel column chromatography (CH 2 Cl 2 :MeOH=40:1) to obtain compound XI-01 (13 mg) as a white solid.

[0327] 1 H-NMR ((CD 3 ) 2 SO)δ10.48(s,1H),8.11(dd,J=9.1,2.3Hz,1H),8.00-7.92(m,1H),7.50(t d,J=9.0,2.4Hz,1H),3.69(s,3H),2.37(s,3H),2.23(s,3H),2.12(s,3H).

[0328] <Example 54> Synthesis of 3-chloro-6-fluoro-N-(5-methoxy-3,4,6-trimethylpyridin-2-yl)-N-methylbenzo[b]thiophene-2-carboxamide (Formula XI-02)

[0329] K 2 CO 3 (17 mg) and CH 3 I (13 μL) was added to a DMF (1 mL) solution of compound X-24 (15 mg) in sequence. The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was diluted with EtOAc and washed with water and saturated brine. The EtOAc solution was filtered through anhydrous MgSO 4 Dry, filter, and concentrate under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc: hexane = 3:7) to obtain compound XI-02 (10 mg) as a yellow solid.

[0330] 1 H-NMR ((CD 3 ) 2SO)δ7.90(dd,J=9.1,2.3Hz,1H),7.78(dd,J=8.9,5.1Hz,1H),7.36(td,J=9.0 ,2.3Hz,1H),3.59(s,3H),3.25(s,3H),2.24(s,4H),2.13(s,3H),2.10(s,3H).

[0331] <General Preparation Process 3 of Example>

[0332] The compounds of Examples 55-59 (Compounds XI-03 to XI-07) were prepared according to the preparation method of the following reaction formula C.

[0333] [Reaction formula C]

[0334]

[0335] In the above reaction formula C,

[0336] R 6a For -(CH 2 )mC(=O)NH(CH 2 )nR b , m, n and R b As defined in this specification.

[0337] NaH (0.3 mmol) and N-substituted-2-chloroacetamide (0.2 mmol) were added to a DMF (1 mL) solution of compound X-24 (0.1 mmol) in sequence, and then stirred at room temperature until compound X-24 disappeared on TLC. The reaction mixture was diluted with EtOAc, washed with water and saturated brine. The EtOAc solution was filtered through anhydrous MgSO 4 Dry, filter, and concentrate under reduced pressure. The resulting residue is purified by silica gel column chromatography to obtain compounds XI-03 to XI-07.

[0338] <Example 55> Synthesis of 3-chloro-6-fluoro-N-(5-(2-(isopropylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide (Formula XI-03)

[0339] The target compound was prepared according to the method of general preparation process 3 of Example.

[0340] 1 H-NMR ((CD 3 ) 2SO) δ10.49(s,1H),8.11(dd,J=9.1,2.3Hz,1H),8.04(d,J=8.1Hz,1H),7.96(dd,J=9.0,5.1Hz,1H),7.50(td,J=9.0,2. 4Hz,1H),4.21(s,2H),4.01(tt,J=13.2,6.6Hz,1H),2.38(s,3H),2.25(s,3H),2.12(s,3H),1.14(s,3H),1.13(s,3H).

[0341] <Example 56> Synthesis of 3-chloro-N-(5-(2-(cyclopropylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)-6-fluorobenzo[b]thiophene-2-carboxamide (Formula XI-04)

[0342] The target compound was prepared according to the method of general preparation process 3 of Example.

[0343] 1 H-NMR (CDCl 3 )δ9.19(s,1H),7.89(dd,J=9.0,4.9Hz,1H),7.53(dd,J=8.3,2.1Hz,1H),7.33-7.22(m,1H),6.86(s,1H),4. 25(s,2H),2.90-2.82(m,1H),2.48(s,3H),2.28(s,3H),2.22(s,3H),0.92-0.84(m,2H),0.68-0.61(m,2H).

[0344] <Example 57> Synthesis of 3-chloro-N-(5-(2-(cyclohexylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)-6-fluorobenzo[b]thiophene-2-carboxamide (Formula XI-05)

[0345] The target compound was prepared according to the method of general preparation process 3 of Example.

[0346] 1 H-NMR (CDCl 3)δ9.25(s,1H),7.90(dd,J=9.0,4.9Hz,1H),7.54(dd,J=8.3,2.2Hz,1H),7.32-7.23( m,1H),6.67(d,J=8.3Hz,1H),4.26(s,2H),3.92(dt,J=10.5,7.4Hz,1H),2.51(s,3H), 2.30(s,3H),2.23(s,3H),2.04-1.97(m,2H),1.81-1.72(m,2H),1.66(dd,J=9.2,3.8 Hz,1H),1.42(ddd,J=15.1,9.0,5.8Hz,2H),1.34-1.26(m,2H),1.21(d,J=3.6Hz,1H).

[0347] <Example 58> Synthesis of N-(5-(2-(benzylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)-3-chloro-6-fluorobenzo[b]thiophene-2-carboxamide (Formula XI-06)

[0348] The target compound was prepared according to the method of general preparation process 3 of Example.

[0349] 1 H-NMR ((CD 3 ) 2 SO)δ10.50(s,1H),8.83(t,J=6.2Hz,1H),8.11(dd,J=9.1,2.3Hz,1H),7.96(dd,J=9.0,5.1Hz,1H),7.50(td,J=9.0,2.4H z,1H),7.37-7.29(m,4H),7.28-7.22(m,1H),4.40(d,J=6.1Hz,2H),4.33(s,2H),2.39(s,3H),2.26(s,3H),2.12(s,3H).

[0350] <Example 59> Synthesis of 3-chloro-6-fluoro-N-(3,4,6-trimethyl-5-(2-oxo-2-(phenylamino)ethoxy)pyridin-2-yl)benzo[b]thiophene-2-carboxamide (Formula XI-07)

[0351] The target compound was prepared according to the method of general preparation process 3 of Example.

[0352] 1 H-NMR ((CD 3 ) 2SO)δ10.53(s,1H),10.14(s,1H),8.13(dd,J=9.0,2.3Hz,1H),7.98(dd,J=8.9,5.1Hz,1H),7.76-7.70(m,2H),7.52 (td,J=9.0,2.4Hz,1H),7.40-7.33(m,2H),7.15-7.09(m,1H),4.49(s,2H),2.45(s,3H),2.32(s,3H),2.16(s,3H).

[0353] <General Preparation Process 4 of Example>

[0354] The compounds of Examples 60-68 (Compounds XI-08 to XI-16) were prepared according to the preparation method of Reaction Formula D below.

[0355] [Reaction formula D]

[0356]

[0357] In the above reaction formula D,

[0358] R 6b -C(=O)R c , R c As defined in this specification.

[0359] Method (1): Et 3 N (0.2 mmol) and acyl chloride (0.1 mmol) were added sequentially to the CH 2 Cl 2 (1 mL) suspension, and then stirred at room temperature until compound X-24 disappeared on TLC. 2 Cl 2 The reaction mixture was diluted and washed successively with water, saturated NaHCO 3 Solution, water and saturated brine. 2 Cl 2 The solution was passed through anhydrous MgSO 4 Dry, filter, and concentrate under reduced pressure. The resulting residue is purified by silica gel column chromatography to obtain compounds XI-08 to XI-16.

[0360] Method (2): EDCI (0.15 mmol), HOBt (0.15 mmol) and Et 3 N (0.25 mmol) was added to a DMF (1 mL) solution of compound X-24 (0.1 mmol). Carboxylic acid (0.2 mmol) was added and the reaction mixture was stirred at room temperature until compound X-24 disappeared on TLC.2 Cl 2 The reaction mixture was diluted and washed successively with water and saturated brine. 2 Cl 2 The solution was passed through anhydrous MgSO 4 Dry, filter, and concentrate under reduced pressure. The resulting residue is purified by silica gel column chromatography to obtain compounds XI-08 to XI-16.

[0361] <Example 60> Synthesis of 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-ylbenzoic acid methyl ester (Formula XI-08)

[0362] The target compound was prepared according to the method (1) of the general preparation process 4 in Example.

[0363] 1 H-NMR ((CD 3 ) 2 SO)δ10.65(s,1H),8.26-8.21(m,2H),8.12(dd,J=9.1,2.3Hz,1H),7.98(dd,J=9.0,5.1Hz,1H),7.84 -7.78(m,1H),7.70-7.63(m,2H),7.51(td,J=9.0,2.4Hz,1H),2.28(s,3H),2.19(s,3H),2.15(s,3H).

[0364] <Example 61> Synthesis of 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 4-fluorobenzoate (Formula XI-09)

[0365] The target compound was prepared according to the method (1) of the general preparation process 4 in Example.

[0366] 1 H-NMR (CDCl 3 )δ9.35(s,1H),8.36-8.20(m,2H),7.91(dd,J=9.0,4.9Hz,1H),7.54(dd,J=8.3,2.1Hz,1H ),7.28(dd,J=8.9,2.3Hz,1H),7.26-7.20(m,2H),2.44(s,3H),2.28(s,3H),2.23(s,3H).

[0367] <Example 62> Synthesis of 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 3-methoxybenzoate (Formula XI-10)

[0368] The target compound was prepared according to the method (1) of the general preparation process 4 in Example.

[0369] 1 H-NMR (CDCl 3 )δ9.21(s,1H),7.89(dd,J=9.0,5.0Hz,1H),7.84(d,J=7.8Hz,1H),7.71(dd,J=2.4,1.5Hz,1H),7.53(dd,J=8 .3,2.2Hz,1H),7.45(t,J=8.0Hz,1H),7.31-7.13(m,3H),3.89(s,3H),2.42(s,3H),2.26(s,3H),2.21(s,3H).

[0370] <Example 63> Synthesis of 4-methoxybenzoic acid 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl ester (Formula XI-11)

[0371] The target compound was prepared according to the method (1) of the general preparation process 4 in Example.

[0372] 1 H-NMR ((CD 3 ) 2 SO)δ10.63(s,1H),8.21-8.15(m,2H),8.12(dd,J=9.1,2.4Hz,1H),7.97(dd,J=8.9,5.1Hz,1H),7. 51(td,J=9.0,2.4Hz,1H),7.21-7.14(m,2H),3.90(s,3H),2.26(s,3H),2.18(s,3H),2.13(s,3H).

[0373] <Example 64> Synthesis of 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 5-fluoropicolinate (Formula XI-12)

[0374] The target compound was prepared according to the method (2) of the general preparation process 4 in Example.

[0375] 1 H-NMR ((CD 3 ) 2SO)δ10.66(s,1H),8.88(d,J=2.9Hz,1H),8.45(dd,J=8.8,4.5Hz,1H),8.13(dd,J=9.1,2.3Hz,1H),8.05(td,J=8 .6, 2.9Hz, 1H), 7.98 (dd, J=9.0, 5.1Hz, 1H), 7.51 (td, J=9.0, 2.4Hz, 1H), 2.28 (s, 3H), 2.20 (s, 3H), 2.16 (s, 3H).

[0376] <Example 65> Synthesis of 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl-6-fluoronicotinate (Formula XI-13)

[0377] The target compound was prepared according to the method (2) of the general preparation process 4 in Example.

[0378] 1 H-NMR ((CD 3 ) 2 SO)δ10.66(s,1H),9.12(d,J=2.5Hz,1H),8.79-8.73(m,1H),8.13(dd,J=9.1,2.3Hz,1H) ,7.98(dd,J=9.0,5.1Hz,1H),7.55-7.47(m,2H),2.29(s,3H),2.20(s,3H),2.17(s,3H).

[0379] <Example 66> Synthesis of 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 5-chloropicolinate (Formula XI-14)

[0380] The target compound was prepared according to the method (2) of the general preparation process 4 in Example.

[0381] 1 H-NMR ((CD 3 ) 2 SO)δ10.66(s,1H),8.93(dd,J=2.4,0.6Hz,1H),8.35(dd,J=8.4,0.6Hz,1H),8.27(dd,J=8.4,2.4Hz,1H),8.12(dd, J=9.1,2.3Hz,1H),7.98(dd,J=9.0,5.1Hz,1H),7.51(td,J=9.0,2.4Hz,1H),2.28(s,3H),2.19(s,3H),2.16(s,3H).

[0382] <Example 67> Synthesis of 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 6-chloropicolinate (Formula XI-15)

[0383] The target compound was prepared according to the method (1) of the general preparation process 4 in Example.

[0384] 1 H-NMR ((CD 3 ) 2 SO)δ10.66(s,1H),9.22(dd,J=2.5,0.6Hz,1H),8.60(dd,J=8.4,2.5Hz,1H),8.12(dd,J=9.1,2.3Hz,1H),7.98(dd, J=9.0,5.1Hz,1H),7.83(dd,J=8.4,0.6Hz,1H),7.51(td,J=9.0,2.4Hz,1H),2.29(s,3H),2.20(s,3H),2.16(s,3H).

[0385] <Example 68> Synthesis of 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl(3r,5r,7r)-adamantane-1-carboxylate (Formula XI-16)

[0386] The target compound was prepared according to the method (1) of the general preparation process 4 in Example.

[0387] 1 H-NMR ((CD 3 ) 2 SO)δ10.58(s,1H),8.12(dd,J=9.1,2.3Hz,1H),7.97(dd,J=9.0,5.1Hz,1H),7. 51(td,J=9.0,2.4Hz,1H),2.20(s,3H),2.15(s,3H),2.07(m,12H),1.76(m,6H).

[0388] <Example 69> Synthesis of 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-ylmorpholine-4-carboxylate (Formula XI-17)

[0389] Compound X-24 (200 mg) and NaH (44 mg) were dissolved in DMF (1.8 mL), 1H-imidazol-1-yl-4-morpholinylmethanone (100 mg) was added thereto, and the mixture was stirred at room temperature for 24 hours. The reaction solution was diluted with EtOAc, and washed with water and saturated brine. The EtOAc solution was filtered through anhydrous MgSO4 The residue was purified by column chromatography (CH 2 Cl 2 :MeOH=99:1) to obtain the target compound XI-17 (40 mg) as a yellow solid.

[0390] 1 H-NMR ((CD 3 ) 2 SO) δ10.57(s,1H),8.12(dd,J=9.1,2.3Hz,1H),7.97(dd,J=9.0,5.1Hz,1H),7.51(td,J=9. 0,2.4Hz,1H),3.68(s,6H),3.45(d,J=12.6Hz,2H),2.26(s,3H),2.15(s,3H),2.12(s,3H).

[0391] The numbers, chemical structures and names of the compounds of the present invention prepared above are summarized in Table 1 below.

[0392] [Table 1]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400]

[0401]

[0402]

[0403] <Experimental Example 1> Activity test for inhibiting TNF-α-induced adhesion of monocytes to intestinal epithelial cells

[0404] <Test method>

[0405] HT-29 human colon cancer epithelial cells and U937 human monocytes were cultured at 37°C and 5% CO 2The cells were cultured in RPMI 1640 medium containing 10% FBS and 1% penicillin / streptomycin (PS) in an incubator. When the cells grew to more than 80% of the bottom area of ​​the culture flask, they were passaged at a ratio of 1:3 and used in this experiment. HT-29 cells were plated in 24-well plates at 2×10 5 Cells / cm 2 The cells were cultured at a density of 100 μg / mL and the test drug was pretreated in a medium containing 1% FBS and 1% PS for 1 hour. Then, 10 μg / mL of BCECF-AM was treated therein and reacted at 37°C for 30 minutes. U937 cells loaded with BCECF and TNF-α (10 ng / mL) were reacted with HT-29 cells pre-treated with the test drug at 37°C for 3 hours. After the reaction was completed, the culture medium was removed and the culture flask was washed twice with PBS to remove the non-adherent U937 cells. In the next step, the cells were lysed by treatment with 0.1% TritonX-100 (0.1M Tris) and reacted at room temperature for 30 minutes. Then, the fluorescence was measured and quantified using a Fluostar Optima microplate reader (BMG Labtechnologies, Germany) (Carvalho et al., 1996; Thapa et al., 2008).

[0406] Carvalho, D., Savage, CO, Black, CM, and Pearson, JD, IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines, J. Clin. Invest. 97, 111-119 (1996).

[0407] Thapa, D., Lee, JS, Park, SY, Bae, YH, Bae, SK, Kwon, JB, Kim, KJ, Kwak, MK, Park, YJ, Choi, HG and Kim, JA, Clotrimazole Ameliorates Intestinal Inflammation and Abnormal Angiogenesis by Inhibiting Interleukin-8 Expression through a Nuclear Factor-kB-Dependent Manner, J. Pharmacol, J. Pharmacol. Exp. Ther. 327, 353-364 (2008).

[0408] [Table 2]

[0409]

[0410] As shown in Table 2, which shows the results of studying the inhibitory activity of the test drug (1 μM) on the adhesion of intestinal epithelial cells (HT-29) and monocytes (U937) induced by TNF-α, the inhibition rate of 5-ASA (positive control, an active metabolite of sulfasalazine, a drug currently used in clinical trials for the treatment of inflammatory bowel disease) was 3.8%, showing a very small effect, while the inhibition rate of the compound X-24 of the present invention was 90.3%, showing very excellent activity.

[0411] In addition, the inhibition rate of compound X-07 was 88.9%, the inhibition rate of compound XI-07 was 84.1%, the inhibition rate of compound X-09 was 82.8%, and the inhibition rate of compound XI-11 was 77.2%.

[0412] The compounds showing an inhibition rate of 50% or more are listed in the following order of superior inhibitory activity: Compound XI-17 > Compound XI-06 > Compound XI-03 > Compound X-10 > Compound X-18 > Compound X-12. Except for Compound XI-09, all other compounds were confirmed to have better inhibitory activity than 5-ASA.

[0413] The above results confirm that the compound represented by Formula 1 of the present invention can be effectively used to treat inflammatory bowel disease, and it can be seen that the compound of the present invention can be used as a substitute for existing drugs.

[0414] <Experimental Example 2> Activity test for inhibiting IL-6-induced adhesion of monocytes and intestinal epithelial cells

[0415] <Test method>

[0416] The inhibitory activity of IL-6 on intestinal epithelial cell-monocyte adhesion was tested using the same method as TNF-α. HT-29 cells were plated in 24-well plates at 2 × 10 5 Cells / cm 2 The cells were cultured at a density of 100 μg / mL and the test drug was pretreated in a culture medium containing 1% FBS and 1% PS for 1 hour. Then, 10 μg / mL BCECF-AM was treated therein and reacted at 37°C for 30 minutes. U937 cells loaded with BCECF and IL-6 (10 ng / mL) were reacted with HT-29 cells pre-treated with the test drug at 37°C for 3 hours. After the reaction was completed, the culture medium was removed and the culture flask was washed twice with PBS to remove the non-adherent U937 cells. In the next step, the cells were lysed by treatment with 0.1% Triton X-100 (0.1 M Tris) and reacted at room temperature for 30 minutes. Then, the fluorescence was measured and quantified using a Fluostar Optima microplate reader (BMG Labtechnologies, Germany).

[0417] [Table 3]

[0418]

[0419]

[0420] As shown in Table 3, which illustrates the results of investigating the inhibitory activity of the test drugs (1 μM) on IL-6-induced adhesion of intestinal epithelial cells (HT-29) and monocytes (U937), at a concentration of 1 μM, the inhibition rate of the existing drug 5-ASA was less than 1.7%, which showed a small effect, while tofacitinib showed an inhibition rate of 49.1%.

[0421] The inhibition rate of the compound X-07 of the present invention was 80.3%, showing very good activity. In addition, the inhibition rate of the compound X-24 was 79.2%, the inhibition rate of the compound XI-07 was 72.8%, the inhibition rate of the compound X-09 was 71.7%, the inhibition rate of the compound XI-11 was 67%, the inhibition rate of the compound XI-17 was 59.6%, and the inhibition rate of the compound XI-06 was 54.1%. It was confirmed that all other compounds had better inhibitory activity than 5-ASA.

[0422] Results of the study on the inhibitory activity of two compounds with excellent activity against TNF-α and IL-6-induced adhesion of intestinal epithelial cells and monocytes (IC 50 ) are shown in Table 4 below.

[0423] [Table 4]

[0424] Compound <![CDATA[TNF-α(IC 50 )]]> <![CDATA[IL-6(IC 50 )]]> 5-ASA 18.1mM 25.1mM Tofacitinib 0.70μM 0.44μM X-09 0.30μM 0.34μM X-24 0.23μM 0.35μM

[0425] As shown in Table 4, for 5-ASA used as a control drug, the IC 50 The IC of inhibition of adhesion by IL-6 was 18.1 mM 50 On the other hand, for the compound X-09 of the present invention, the IC values ​​for inhibiting adhesion by TNF-α and IL-6 were 50 For compound X-24, the IC values ​​for inhibition of adhesion by TNF-α and IL-6 were 0.30 μM and 0.34 μM, respectively. 50 The compounds X-09 and X-24 showed excellent activities tens of thousands of times higher than 5-ASA, and also showed better activities than tofacitinib.

[0426] The above results confirm that the compound represented by Formula 1 of the present invention can be effectively used to treat inflammatory bowel disease, and it can be seen that the compound of the present invention can be used as a substitute for existing drugs.

[0427] <Experimental Example 3> In vivo efficacy test of oral compounds in TNBS-induced inflammatory bowel disease rat model

[0428] <Test method>

[0429] SD rats (Sprague Dawley rats) aged 7-8 weeks were purchased from OrientBio (Korea), stabilized with general solid feed for 3 days, and then used in this experiment. Feed and water were freely supplied during the experiment, and the temperature of the feeding room was maintained at 25 ± 1 ° C, and the relative humidity was maintained at 50 ± 10%. Lighting management was controlled by an automatic lighting controller with a 12-hour light-dark cycle. The experimental group was divided into 5 groups (control group, TNBS treatment group alone, TNBS + sulfasalazine (300 mg / kg) treatment group, TNBS + tofacitinib (30 mg / kg) treatment group, TNBS + test drug (1 mg / kg) treatment group), wherein each group of 6 animals, and according to the random block design, the average body weight was 180 ± 10g.

[0430] (1) Inducing enteritis by rectal administration of TNBS

[0431] After the rats were anesthetized with ether and fasted for 24 hours, 0.8 mL of 5% TNBS diluted with 50 v / v% ethanol was slowly injected into the colon lumen using a 1 mL syringe connected to a polyethylene catheter, and then the rats were placed upside down for 60 seconds to prevent 5% TNBS from leaking into the anus. For the control group, only the solvent [50 v / v% ethanol] was injected in the same manner as other groups (Thapa et al., 2008).

[0432] (2) Drug administration

[0433] To study the effect of the drug, the drug was administered at a fixed time every day for 5 days starting from the day after TNBS treatment.

[0434] (3) Weight observation

[0435] The body weight changes of each rat from the fasting period to the TNBS administration and drug administration were observed using a digital mass meter.

[0436] (4) Measurement of colon weight

[0437] The colon of the rat was removed, the tissue 5-6 cm from the anus was cut into a length of 1 cm, and the weight of the tissue was measured.

[0438] (5) Staining of colon tissue and measurement of mucosal damage

[0439] The rat tissues weighed were fixed with 4% paraformaldehyde solution and then transferred to 30% sucrose solution. When the tissues settled, they were taken out and cut into 25 μm thick with a freezing microtome (Microm HM 450, Thermo Fisher Scientific, Germany), and stored in a cryopreservation solution. After washing the tissue sections with KPBS, the tissue sections were attached to a slide, dried, then stained with hematoxylin and eosin and observed under a microscope. Mucosal injury and recovery were scored as shown in Table 5 below, and it was confirmed that each rat had a total score of 6 points.

[0440] [Table 5]

[0441]

[0442] <Analysis of the effects of oral administration of compounds on TNBS-induced enteritis>

[0443] The compounds showing excellent activity in the in vitro adhesion inhibition test were tested for in vivo enteritis inhibitory activity at a fixed dose (1 mg / kg) as intestinal weight recovery rate and body weight recovery rate, and the results are shown in Table 6. In addition, the dose-dependent activity of compound X-09 is shown in Table 7.

[0444] [Table 6]

[0445]

[0446]

[0447] [Table 7]

[0448]

[0449] 1. Weight changes

[0450] In rats weighing 180-190g, in a colitis model induced by intestinal inflammation treated with 5% TNBS, weight changes were observed at a certain time every day for 5 days based on the weight before TNBS treatment. As a result, the weight of the rats in the solvent-treated control group continued to increase, and the weight of the rats in the TNBS-treated group continued to decrease. From the 5th day, the weight was slightly restored, but the weight was significantly reduced compared with the normal group rats. The weight of rats treated with 300mg / kg of sulfasalazine in the positive control group gradually recovered. Although the weight was reduced compared with the rats in the solvent-treated control group, the weight was significantly increased compared with the rats treated with TNBS alone, resulting in a weight recovery rate of 50.5%. When administered at 1mg / kg, the pyridinol compound showed a recovery rate of 60.2%-86.6%. The compounds are listed in the order of excellent weight recovery rate as follows: Compound X-24, XI-07, X-09 and XI-17. For compound X-09, the dose-dependent activity was measured by adding 10 mg / kg triamcinolone acetonide to 300 mg / kg sulfasalazine in the positive control group. The results confirmed that compound X-09 exhibited dose-dependent body weight restoration activity and was more effective than triamcinolone at the same concentration.

[0451] 2. Morphological Observation

[0452] After 5 days of administration, the colon was removed and visually examined. As a result, compared with the control group rats, the colon of the rats treated with TNBS showed edema and congestion, and appendiceal edema and congestion and intestinal tissue adhesion were observed. In the group treated with 300 mg / kg sulfasalazine (positive control group), the symptoms observed by the naked eye and adhesions between other organs and colon congestion were also significantly suppressed. In the group treated with the pyridinol compound, the symptoms were improved more than the group treated with 300 mg / kg sulfasalazine. It was also confirmed that compound X-09 showed dose-dependent therapeutic activity for enteritis and was more effective than triamcinolone acetonide at the same concentration.

[0453] 3. Measurement of Colon Weight

[0454] The degree of inflammation in the rat colon is a key measure (important indicator) of IBD progression, which is more important than weight change. The colon was extracted and the tissue weight was measured 5-6 cm from the anus. As a result, the weight of the edematous colon in the rat group treated with TNBS alone increased significantly compared with the control group rats treated with solvent. In the rat group treated with 300 mg / kg sulfasalazine (positive control), the weight recovery rate of colon tissue was 69.6%. When administered at 1 mg / kg, pyridinol compounds showed a recovery rate of 79.8%-97.4%. The compounds are listed in order of excellent weight recovery rate as follows: Compound X-24, XI-07, X-09 and XI-17. It was also confirmed that compound X-09 showed dose-dependent weight recovery activity and was more effective than triamcinolone at the same concentration.

[0455] 4. Measurement of Recovery of Colonic Mucosal Injury in Rats

[0456] After observing the morphology of the colon in the dose-dependent activity measurement experiment, hematoxylin-eosin staining of colon tissue was performed to score and compare the degree of colon mucosal injury. As a result, it was confirmed that compound X-09 showed dose-dependent mucosal injury restoration activity and was more effective than triamcinolone at the same concentration (Figure 1).

[0457] From the results of Experimental Example 3, it is confirmed that the compound represented by Formula 1 of the present invention can be effectively used to treat inflammatory bowel disease, and it can be seen that the compound of the present invention can be used as a substitute for existing drugs.

[0458] <Experimental Example 4> In vivo efficacy test of oral compounds in a dextran sulfate sodium (DSS)-induced inflammatory bowel disease mouse model

[0459] <Test method>

[0460] 7-8 week old C57BL / 6 mice were purchased from OrientBio (Korea), stabilized with general solid feed for 7 days, and then used in this experiment. Feed and water were freely supplied during the experiment, and the temperature of the breeding room was maintained at 25±1°C and the relative humidity was maintained at 50±10%. Lighting management was controlled by an automatic lighting controller with a 12-hour light-dark cycle.

[0461] (1) DSS-induced acute and chronic enteritis and determination of drug prevention and treatment effects

[0462] Intestinal inflammation was induced in mice by allowing them to freely consume drinking water containing 2% DSS salt (MW, 36,000-50,000, MP Biomedicals, LLC, OH, USA). For the chronic intestinal inflammation model, a DSS administration regimen was used in which DSS was administered for the first 7 days, normal drinking water was administered for 14 days, and DSS administration was repeated for 7 days starting from day 21, and normal drinking water was administered for 7 days. The drug was administered once a day for 6 days a week from the first day of DSS treatment ( Figure 2A The experimental group was divided into 6 groups (control group, DSS treatment group, DSS + sulfasalazine (300 mg / kg) treatment group, DSS + tofacitinib (30 mg / kg) treatment group, DSS + test drug (1 mg / kg) treatment group and DSS + test drug (3 mg / kg) treatment group), each of which had 6 animals and the average body weight was 20±1g according to the randomized block design. In order to measure the dose-dependent therapeutic effect of the drug in the acute enteritis model, DSS was given for 5 days to induce enteritis, and then the drug was given for 14 days to measure the recovery and treatment degree of enteritis ( Figure 3A ). The drug is taken orally at a fixed time, once a day, for 10 days.

[0463] (2) Weight observation

[0464] During the DSS and drug administration periods, the body weight changes of each mouse were observed using a digital mass meter.

[0465] (3) Measurement of colon length and weight

[0466] The colon of mice was extracted, and the length and weight from anus to cecum were measured.

[0467] (4) Measuring MPO

[0468] The degree of neutrophil infiltration in the tissue was measured by the amount of MPO (neutrophil marker enzyme). Colon tissue of 1 cm in size was washed with cold PBS and weighed, to which lysis buffer (pH 7.4, 200 mM NaCl, 5 mM EDTA, 10 mM tris, 10% glycerol, 1 mM PMSF, 1 μg / mL leupeptin and 28 μg / mL aprotinin) (500 μL / 10 mg tissue weight) was added, and then the colon tissue was lysed with Beads. D2400 homogenizer (Beadmark Scientific, NJ, USA) was used for homogenization. The homogenized sample was centrifuged twice at 1500×g for 5 minutes to obtain the supernatant, and then 100 μL of the supernatant was measured using a kit. The homogenized sample was centrifuged twice at 1500×g for 5 minutes to obtain the supernatant, and then 100 μL of the supernatant was measured using an MPO ELISA kit (HK210, Hycult Biotechnology, the Netherlands). The supernatant was added to a 96-well plate (100 μL / well) coated with an anti-mouse MPO antibody, incubated at room temperature for 1 hour, and then washed 3 times with wash buffer. The reconstituted tracer was added to the plate (100 μL / well), reacted at room temperature for 1 hour, washed 3 times, and then 100 μL of streptavidin-peroxidase conjugate was added to each well of the plate. The plate was reacted at room temperature for 1 hour, washed, and 100 μl of TMB substrate solution was added to each well of the plate, followed by a reaction of 30 minutes. The reaction was stopped by adding 100 μL of stop solution to each well of the plate and the absorbance was measured at 450 nm. MPO activity refers to the amount of 1 μM hydrogen peroxide reduced from water in 1 minute at 25°C. This was calculated as the amount of MPO contained in 1 mL of colon tissue homogenate.

[0469] (5) Tissue staining

[0470] Histological staining was performed in the same manner as hematoxylin / eosin staining of rat colon tissue, and the scoring index of mucosal injury and recovery was applied in the same manner.

[0471] <Analysis of the effects of oral administration of compounds on DSS-induced acute and chronic enteritis in mice>

[0472] The inhibitory activity of compound X-24 on DSS-induced chronic mouse enteritis was determined, and the results are shown in Table 8. The dose-dependent therapeutic effect of compound X-09 on DSS-induced acute mouse enteritis was determined, and the results are shown in Table 9.

[0473] [Table 8]

[0474]

[0475] [Table 9]

[0476]

[0477] 1. Weight changes

[0478] In the chronic enteritis model, chronic inflammation was induced in mice weighing 19-21 g by providing water containing 2% DSS for 7 days, water for 14 days, and then water containing 2% DSS for 7 days, and the efficacy of the pyridinol compound was measured. Changes in body weight were observed in the chronic enteritis model. As a result, the body weight of the control group mice treated with the solvent (vehicle) continued to increase, and the body weight of the DSS-treated group mice decreased due to the DSS treatment, and began to recover body weight when drinking water, but the body weight decreased significantly again due to the second administration of DSS. Compared with the solvent-treated control group mice, the weight recovery rates of the mice in the group treated with 300 mg / kg sulfasalazine or 30 mg / kg tofacitinib (positive control group) after 35 days were 22.8% and 29.4%, respectively. On the other hand, the mice in the group treated with the pyridinol compound X-24 showed a dose-dependent weight recovery rate (22.8%, 73.3%) ( Figure 2B ).

[0479] In the acute enteritis model, enteritis was induced by providing water containing 2% DSS in mice weighing 19-21 g for 7 days, and the weight change based on the weight before DSS treatment was observed at a certain time every day. As a result, the weight of the mice in the solvent-treated control group continued to increase, and the weight of the mice in the DSS-treated group continued to decrease, so that the body weight was significantly reduced compared with the normal group mice. The weight of mice treated with sulfasalazine 300 mg / kg or tofacitinib 30 mg / kg in the positive control group gradually recovered, and although the weight was reduced compared with the solvent-treated control group rats, the weight was significantly increased compared with the weight of mice treated with DSS alone, resulting in a weight recovery rate of 65.9% and 80.9%, respectively. The dose-dependent efficacy of oral administration of compound X-09 on DSS-induced acute enteritis was measured. As a result, the mouse groups treated with pyridinol compound X-09 showed weight recovery rates of 56.5, 72.0, 80.7 and 88.1% ( Figure 3B ).

[0480] 2. Morphological Observation

[0481] After 7 days of administration, the colon was removed and visually inspected. As a result, the colon of mice treated with DSS was significantly shorter than that of the control group, and edema and congestion were observed. In addition, edema and congestion of the appendix and adhesion of intestinal tissue were observed. In the group treated with 300 mg / kg sulfasalazine or 30 mg / kg tofacitinib (positive control group), recovery of intestinal length was observed, and macroscopic symptoms and adhesions between other organs and colon congestion were also significantly suppressed. In the group treated with the pyridinol compound, it was observed that the symptoms were improved more than those of the group treated with 30 mg / kg tofacitinib and the group treated with 300 mg / kg sulfasalazine ( Figure 2CCompound X-09 showed a dose-dependent therapeutic effect, and the therapeutic effect in the group treated with 10 mg / kg of Compound X-09 was significantly better than that in the control group treated with 30 mg / kg of Tofacitinib ( Figure 3C ).

[0482] 3. Measurement of Colon Weight

[0483] The colon of the mice was extracted and the tissue weight between the anus and the cecum was measured. As a result, the weight of the edematous colon of the mice in the DSS-treated group alone was significantly increased compared with the control group of mice treated with the solvent. In the chronic enteritis model, the recovery rate of intestinal tissue weight of mice treated with 300 mg / kg sulfasalazine or 30 mg / kg tofacitinib (positive control) was 67.3% and 68.8%, respectively. Compound X-24 showed a dose-dependent recovery rate (58.1% and 98.2%) at 1 mg / kg and 3 mg / kg ( Figure 2D ).

[0484] The therapeutic efficacy of the compound was measured in an acute enteritis model. As a result, intestinal tissue weight recovery was observed in the group treated with 300 mg / kg sulfasalazine or 30 mg / kg tofacitinib (positive control). Compound X-09 showed a dose-dependent effect, showing better effects than the positive control group at 3 mg / kg and 10 mg / kg ( Figure 3D ). In addition, the level of MPO, a biochemical indicator of tissue inflammation, was measured. As a result, the significantly increased level of MPO caused by DSS was dose-dependently reduced by compound X-09, and the groups treated with compound X-09 at concentrations of 3 mg / kg and 10 mg / kg showed better effects than the positive control group ( Figure 3E ).

[0485] 4. Measurement of recovery of mouse colonic mucosal injury

[0486] After observing the morphology of the colon in the dose-dependent activity measurement experiment, hematoxylin-eosin staining of the colon tissue was performed to score and compare the extent of colon mucosal damage. As a result, compound X-09 showed a dose-dependent mucosal damage recovery effect, and it was confirmed that the effect was superior to the control group tofacitinib (Figure 4).

[0487] The results of Experimental Example 4 confirm that the compound represented by Formula 1 of the present invention can be effectively used to treat inflammatory bowel disease, and it can be seen that the compound of the present invention can be used as a substitute for existing drugs.

[0488] <Experimental Example 5> In vivo efficacy test of oral compounds in collagen-induced rheumatoid arthritis animal model

[0489] <Test method>

[0490] Normal male mice and arthritis-induced DBA / 1J mice aged 12 weeks were purchased from Central Laboratory Animal Co. [For arthritis induction, DBA / 1J mice were sensitized at 8 weeks of age by intradermal injection of a mixed solution of complete Freund's adjuvant (CFA; DIFCO, Detroit, MI) and bovine type II collagen (1:1, v / v) at the base of the auricle and then sensitized again at 11 weeks of age by intradermal injection in the tail]. The purchased arthritic mice were acclimated to the laboratory environment for one week before oral administration.

[0491] (1) Visual observation and measurement of arthritis

[0492] Arthritic lesions were visually observed using the following score based on reference (Barnett et al., 1998).

[0493] 0: No edema or swelling,

[0494] 1: Mild swelling or redness of the foot or ankle joint.

[0495] 2: Mild swelling and redness from ankle to tarsal bone,

[0496] 3: Moderate swelling and redness from ankle to tarsal bone,

[0497] 4: Swelling, redness and joint stiffness from the ankle to the entire leg.

[0498] Therefore, the maximum score of arthritis lesions was 16 points per mouse. Observations were performed twice a week for 5 weeks from the date of administration, and the evaluation data were prepared by two persons who were not familiar with the experimental and control groups.

[0499] Additionally, photographs are taken to visually determine the extent of arthritis.

[0500] (2) Determination of hind paw thickness

[0501] Hind paw thickness was measured using a caliper, which is one of the pathological indicators of rheumatoid arthritis.

[0502] (3) Joint tissue staining

[0503] The right hind leg of each mouse was taken out, and all skin and muscle were removed, leaving only bones and joints. The hind leg was fixed in 4% paraformaldehyde solution for 2 days, then soaked in 10% formic acid for 5 days to decalcify, and then soaked in 30% sucrose solution. When the tissue subsided, the joint tissue was cut into 30 μm thick with a freezing microtome (Microm HM 450, Thermo Fisher Scientific, Germany) and stored in a cryopreservation solution. The preserved tissue sections were used for staining. After the tissue sections were attached to the slides, they were hydrated with 100%, 95%, 70% and 50% ethanol solutions, some were stained with safranin, and others were stained with hematoxylin / eosin. For safranin staining, the tissue sections were first stained with 0.1% fast green solution, washed with 1% acetic acid solution, and then stained with 1% safranin solution. Then, in the reverse order of hydration, the tissue sections were dehydrated by immersion in an ethanol solution, then preserved in a xylene solution and a sealing solution, and photographed under a microscope. Hematoxylin / eosin staining was performed in the same manner as colon tissue staining. Tissue sections were dehydrated, stored in xylene solution and mounting solution, and observed under a microscope.

[0504] The extent of microscopic tissue damage in the stained joint tissue was measured using the following score.

[0505] Grade 1: No damage to the joint surface.

[0506] Grade 2: The articular surface is discontinuous.

[0507] Level 3: Vertical cracks appear at the joints.

[0508] Level 4: Corrosion at joints,

[0509] Grade 5: Exposed joint erosion,

[0510] Grade 6: joint deformity.

[0511] (4) Lymphocyte isolation and stimulation

[0512] After extracting the spleen and draining lymph nodes of mice, the number of immune cells was counted. To determine the distribution of Th1 and Th17 cells, immune cells obtained from each organ were stimulated with PMA / ionomycin and Golgi stop.

[0513] The proportion of inflammatory cells in total immune cells was confirmed by flow cytometry after staining with anti-IFN-γ antibody that recognizes Th1 cells, anti-IL-17 antibody that recognizes Th17 cells, and anti-CD8 antibody that recognizes cytotoxic T cells.

[0514] Barnett ML, Kremer JM, St Clair EW, Clegon DO, Furst D, Weisman M, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998;41:290-7.

[0515] <Analysis of the effect of oral administration of compound X-09 on collagen-induced rheumatoid arthritis (CIA) animal model>

[0516] The visual score of the degree of arthritis and the change in body weight are shown in Figure 5. The average arthritis score of mice induced with arthritis was 12.8, which was almost at a similar level until the 4th day of administration. The degree of arthritis in the mice in the solvent administration group did not improve, and the arthritis index was 13.8 points on the 35th day. However, when tofacitinib or compound X-09 was administered, the degree of arthritis was significantly improved in a dose-dependent manner. On the 35th day of administration, the group treated with 50 mg / kg compound X-09 showed the best efficacy, with an arthritis score of 7.2, followed by the group treated with 50 mg / kg tofacitinib, the group treated with 10 mg / kg compound X-09, and the group treated with 1 mg / kg compound X-09 ( Figure 5A On the fourth day of administration, the thickness of the hind paws of arthritic mice was 2.58-2.61 mm, which was significantly increased compared with the average hind paw thickness of 1.64 mm in normal mice. On the 35th day of administration, the increase in hind paw thickness caused by inflammatory edema remained at 2.65 mm. In the group treated with 50 mg / kg of compound X-09, the hind paw thickness was significantly reduced to 1.70 mm. The hind paw thickness decreased in the order of the group treated with 50 mg / kg tofacitinib, the group treated with 10 mg / kg of compound X-09, and the group treated with 1 mg / kg of compound X-09 ( Figure 5B Compared with normal mice of the same age, the body weight of arthritic mice was significantly reduced, and the body weight gradually recovered in proportion to the degree of improvement of arthritis ( Figure 5C ).

[0517] Weekly changes in the extent of arthritis in the hind paws are shown in the photographs ( Figure 6 ). The joint tissues were stained with hematoxylin and eosin and safranin O, and the degree of recovery of the joint tissues was converted into a score ( FIG. 7 ).

[0518] After 35 days of administration, immune cells were isolated from the spleen and draining lymph nodes and analyzed. The results confirmed that the total number of immune cells in the spleen was not significantly different from that in the normal group ( Fig. 8A ), but the number of inflammatory cells Th1 and Th17 and the number of activated CD8 cells were significantly reduced. The above results confirm that compound X-09 reduces the dose-dependent Figure 8B The number of inflammatory cells Th1 and Th17 and activated CD8 cells secreting interferon-γ in the draining lymph nodes was also significantly reduced ( Figure 8C ), compound X-09 showed a dose-dependent effect.

[0519] From the above results, it can be confirmed that the compound represented by formula 1 of the present invention can be effectively used for treating rheumatoid arthritis.

[0520] Therefore, as confirmed by the above experiments, the compound of the present invention can be effectively used as a pharmaceutical composition for preventing and treating autoimmune diseases, particularly inflammatory bowel disease or rheumatoid arthritis.

Claims

1. A compound represented by formula 1 or a pharmaceutically acceptable salt thereof: [Formula 1] In formula 1, A is NR a , O or S, wherein the R a is hydrogen or a straight or branched chain C 1-5 alkyl; R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, halogen, straight chain or branched C 1-5 Alkyl, or straight chain or branched C 1-5 Alkoxy, wherein the alkyl and alkoxy groups may be independently substituted with one or more halogens; R 6 is hydrogen, straight chain or branched chain C 1-5 Alkyl, -(CH2)mC(=O)NH(CH2)nR b or -C(=O)R c , wherein the alkyl group may be substituted with one or more halogens, and m and n are independently integers from 0 to 5, R b is hydrogen, straight chain or branched chain C 1-10 Alkyl, C 3-10 Cycloalkyl or C 6-10 Aryl, R c is adamantyl, a 3-10 membered heterocycloalkyl containing one or more heteroatoms selected from N, O and S, C 6-10 aryl, or a 5-10 membered heteroaryl containing one or more heteroatoms selected from N, O and S, wherein the aryl and heteroaryl can be independently substituted with at least one selected from halogen, straight chain or branched C 1-5 Alkyl and straight or branched chain C 1-5 Alkoxy group substitution; R 7 , R 8 and R 9 are independently linear or branched C 1-5 Alkyl; and R 10 is hydrogen, or a straight or branched chain C 1-5 alkyl.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: A is NR a , O or S, wherein the R a is hydrogen, or a straight or branched chain C 1-3 alkyl; R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, halogen, straight chain or branched C 1-3 Alkyl, or straight chain or branched C 1-3 Alkoxy, wherein the alkyl and alkoxy groups may be independently substituted with one or more halogens; R 6 is hydrogen, straight chain or branched chain C 1-3 Alkyl, -(CH2)mC(=O)NH(CH2)nR b or -C(=O)R c , wherein the alkyl group may be substituted with one or more halogens, and m and n are independently integers from 0 to 3, R b is hydrogen, straight chain or branched chain C 1-6 Alkyl, C 3-8 Cycloalkyl or phenyl, R c is adamantyl, a 3-8 membered heterocycloalkyl containing one or more heteroatoms selected from N, O and S, a phenyl group, or a 5-6 membered heteroaryl containing one or more heteroatoms selected from N, O and S, wherein the phenyl group and the heteroaryl group may be independently substituted with at least one selected from halogen, straight chain or branched C 1-3 Alkyl and straight or branched chain C 1-3 Alkoxy group substitution; R 7 , R 8 and R 9 are independently linear or branched C 1-3 Alkyl; and R 10 is hydrogen, or a straight or branched chain C 1-3 alkyl.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: A is NR a , O or S, wherein the R a is hydrogen or methyl; R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, -Cl, -Br, -F, methyl, methoxy, -CF3 or -OCF3; R 6 is hydrogen, methyl, -(CH2)mC(=O)NH(CH2)nR b or -C(=O)R c , where m is 1 and n is 0 or 1, R b is hydrogen, straight chain or branched chain C 1-3 Alkyl, C 3-6 Cycloalkyl or phenyl, R c is adamantyl, a 6-membered heterocycloalkyl containing one or more heteroatoms selected from N, O and S, a phenyl group, or a 6-membered heteroaryl containing one or more heteroatoms selected from N, O and S, wherein the phenyl group and the heteroaryl group may be independently substituted with at least one selected from halogen and a straight or branched C 1-3 Alkoxy group substitution; R 7 , R 8 and R 9 is methyl; and R 10 It is hydrogen or methyl.

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: R 6 is hydrogen, methyl, -(CH2)C(=O)NHR b or -C(=O)R c , R b is hydrogen, isopropyl, cyclopropyl, cyclohexyl, phenyl or benzyl, R c is adamantyl, morpholinyl, phenyl or pyridyl, wherein the phenyl and pyridyl groups may be independently substituted by at least one group selected from F, Cl and methoxy.

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound represented by Formula 1 is selected from the following compounds: <27> N-(5-Hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <28> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1-methyl-1H-indole-2-carboxamide; <29> 7-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <30> 6-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <31> 6-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <32> 5-Fluoro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <33> 5-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <34> 5-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-1H-indole-2-carboxamide; <35> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-methyl-1H-indole-2-carboxamide; <36> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethyl)-1H-indole-2-carboxamide; <37> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-(trifluoromethoxy)-1H-indole-2-carboxamide; <38> N-(5-Hydroxy-3,4,6-trimethylpyridin-2-yl)-6-methoxy-1H-indole-2-carboxamide; <39> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5-methoxy-1H-indole-2-carboxamide; <40> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-5,6-dimethoxy-1H-indole-2-carboxamide; <41> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide; <42> 5-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide; <43> 5-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzofuran-2-carboxamide; <44> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-7-methoxybenzofuran-2-carboxamide; <45> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-3-methylbenzofuran-2-carboxamide; <46> N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <47> 3-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <48> 3-Bromo-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide;<49> 3-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-6-methylbenzo[b]thiophene-2-carboxamide; <50> 3-Chloro-6-fluoro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <51> 3,6-Dichloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <52> 3-Chloro-N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)-6-methoxybenzo[b]thiophene-2-carboxamide; <53> 3-Chloro-6-fluoro-N-(5-methoxy-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <54> 3-Chloro-6-fluoro-N-(5-methoxy-3,4,6-trimethylpyridin-2-yl)-N-methylbenzo[b]thiophene-2-carboxamide; <55> 3-Chloro-6-fluoro-N-(5-(2-(isopropylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)benzo[b]thiophene-2-carboxamide; <56> 3-Chloro-N-(5-(2-(cyclopropylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)-6-fluorobenzo[b]thiophene-2-carboxamide; <57> 3-Chloro-N-(5-(2-(cyclohexylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)-6-fluorobenzo[b]thiophene-2-carboxamide; <58> N-(5-(2-(Benzylamino)-2-oxoethoxy)-3,4,6-trimethylpyridin-2-yl)-3-chloro-6-fluorobenzo[b]thiophene-2-carboxamide; <59> 3-Chloro-6-fluoro-N-(3,4,6-trimethyl-5-(2-oxo-2-(phenylamino)ethoxy)pyridin-2-yl)benzo[b]thiophene-2-carboxamide; <60> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl benzoate; <61> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 4-fluorobenzoate; <62> 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 3-methoxybenzoate; <63> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 4-methoxybenzoic acid; <64> 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 5-fluoropicolinate; <65> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 6-fluoronicotinate;<66> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl 5-chloropicolinate; <67> 6-(6-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl-6-chloropicolinate; <68> 6-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-yl(3r,5r,7r)-adamantane-1-carboxylate; <69> 6-(3-chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-2,4,5-trimethylpyridin-3-ylmorpholine-4-carboxylate. ; 6. A method for preparing a compound of formula 1, the method comprising the step of preparing a compound of formula 1 by reacting a compound of formula 2 with a compound of formula 3, as shown in the following reaction formula 1: [Reaction formula 1] In reaction formula 1, A.R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 As defined in formula 1 of claim 1.

7. A method for preparing a compound of formula 1b, the method comprising the following steps: As shown in the following reaction formula 2: Step 1: preparing a compound represented by Formula 4 by reacting a compound represented by Formula 2a with a compound represented by Formula 3; Step 2: preparing a compound represented by Formula 1a by deprotecting the compound represented by Formula 4 obtained in the above Step 1; as well as Step 3: Prepare a compound represented by Formula 1b by reacting the compound represented by Formula 1a obtained in the above Step 2 with a compound represented by Formula 5: [Reaction 2] In reaction formula 2, A.R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 As defined in formula 1 of claim 1, but R 6 Except when it is hydrogen; The compound represented by Formula 1a is a derivative of Formula 1, wherein R 6 It is hydrogen; The compound shown in Formula 1b is a derivative of Formula 1, but R 6 Except when it is hydrogen; PG 1 is an alcohol protecting group selected from the group consisting of acetyl, benzoyl, benzyl, methylthiomethyl, β-methoxyethoxymethyl, bis-(4-methoxyphenyl)benzyl, methoxymethyl, (4-methoxyphenyl)diphenylmethyl, p-methoxybenzyl, pivaloyl and trityl; and X is halogen.

8. Use of the compound of formula 1 or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a medicament for preventing or treating inflammatory bowel disease or rheumatoid arthritis.

9. The use according to claim 8, wherein the inflammatory bowel disease is enteritis.

10. The use according to claim 8, wherein the inflammatory bowel disease is colitis.

11. The use according to claim 8, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

12. The use according to claim 8, wherein the inflammatory bowel disease is a bleeding rectal ulcer or a peptic ulcer.